HETEROCYCLE AMINES AND USES THEREOF

Description

FIELD OF THE INVENTION

Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

BACKGROUND

The recruitment of immune cells to sites of injury involves the concerted interactions of a large number of soluble mediators. Several cytokines appear to play roles in these processes, for example, IL-1 and TNF. Both cytokines are derived from mononuclear cells and macrophages along with other cell types. Physiologically, they produce many of the same proinflammatory responses, including fever, sleep, anorexia, mobilization and activation of polymorphonuclear leukocytes, induction of cyclooxygenase and lipoxygenase enzymes, increase in adhesion molecule expression, activation of B-cells, T-cells and natural killer cells, and stimulation of production of other cytokines. Other actions include a contribution to the tissue degeneration seen in chronic inflammatory conditions, such as stimulation of fibroblast proliferation, induction of collagenase, etc. They have also been implicated in the process of bone resorption and adipose tissue regulation. Thus, these cytokines play key roles in a large number of pathological conditions, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, diabetes, obesity, cancer, and sepsis.

The role of IL-1 in inflammation has been demonstrated by the ability of the highly specific IL-1 receptor antagonist protein (IL-1 Ra, or TRAP) to relieve inflammatory conditions. IL-1 treatment of cells induces the formation of a complex consisting of the two IL-1 receptor chains, IL-IRI and IL-1 RAcP, and the resulting heterodimer recruits an adaptor molecule designated as MyD88. MyD88 binds to a protein designated IRAK (Interleukin-1 Receptor-Associated Kinase). IRAK is subsequently phosphorylated and released from the receptor complex to interact with a tumor necrosis factor receptor-associated factor, TRAF6, which transduces the signal to downstream effector molecules. TRAF6 can trigger the NIK/IKK kinase cascade to activate the transcription factor NF-κB. NF-κB regulates a number of genes that, in turn, regulate immune and inflammatory responses.

Four IRAKs have been identified: IRAK-1, IRAK-2, the monomyeloic cell-specific IRAK-M, also known as IRAK-3, and IRAK-4. IRAK proteins have been shown to play a role in transducing signals other than those originating from IL-I receptors, including signals triggered by activation of IL-18 receptors and LPS receptors. Overexpression of IRAK-2 and IRAK-M has been shown to be capable of reconstituting the response to IL-1 and LPS in an IRAK deficient cell line.

SUMMARY OF THE INVENTION

Compounds, compositions and methods of using heterocycle amines are disclosed. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Some embodiments include a compound of Formula (I):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

custom-character is a single or double bond;

W is selected from CH, CH—CH, O, S, NR⁶, and CO;

Y is N or CR⁹;

Z is N or C, and Z is N if W is CH and Y is CR⁹;

R⁴is selected from hydrogen, halogen, OR⁶, CN, NR⁷R⁸, CH₂OR⁶, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆heteroalkyl, an optionally substituted C₁-C₆alkenyl, an optionally substituted C₁-C₆alkynyl, CO₂R⁶, SO₃R⁶, SO₂R⁶and SO₂NR⁷R⁸;

R⁵is selected from hydrogen, halogen, OR⁶, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆heteroalkyl, an optionally substituted C₁-C₆haloheteroalkyl, an optionally substituted C₁-C₆alkenyl, and an optionally substituted C₁-C₆alkynyl;

or R⁴and R⁵are linked to form an optionally substituted non-aromatic ring;

each R⁶is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted C₁-C₁₀alkyl, an optionally substituted C₁-C₁₀haloalkyl, and an optionally substituted C₁-C₁₀heteroalkyl;

each R⁷and R⁸is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted C₁-C₁₀alkyl, an optionally substituted C₁-C₁₀haloalkyl, an optionally substituted C₁-C₁₀alkenyl, an optionally substituted C₁-C₁₀alkynyl, and an optionally substituted C₁-C₁₀heteroalkyl, or R⁷and R⁸are linked to form an optionally substituted non-aromatic ring;

R⁹is selected from hydrogen, halogen, OR⁶, CN, NR⁷R⁸, CH₂OR⁶, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆heteroalkyl, an optionally substituted C₁-C₆alkenyl, an optionally substituted C₁-C₆alkynyl, CO₂R⁶, SO₃R⁶, and SO₂NR⁷R⁸;

A is an optionally substituted aryl or an optionally substituted heteroaryl group;

each optionally substituted group is either unsubstituted or substituted with one or more groups independently selected from alkyl, heteroalkyl, alkenyl, alkynyl, haloalkyl, heterohaloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic ring, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, ═O, ═S, amino, and protected derivatives of amino groups.

In some embodiments, R⁴is selected from hydrogen, halogen, OR⁶, CN, NR⁷R⁸, CH₂OR⁶, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆heteroalkyl, an optionally substituted C₁-C₆alkenyl, an optionally substituted C₁-C₆alkynyl, CO₂R⁶, SO₃R⁶, SO₂R⁶and SO₂NR⁷R⁸

In some embodiments, if R⁴is pyrazolyl, the pyrazolyl is not substituted with aryl or heteroaryl groups.

In some embodiments, if R⁴is oxazolyl, isoxazolyl, or imidazoyl, the oxazolyl, isoxazolyl, or imidazoyl radical is not substituted with aryl or heteroaryl groups.

Some embodiments include a compound represented by Formula (I-A):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

X is N or CR⁵′, wherein R⁵′ is selected from hydrogen, halogen, OR⁶, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆heteroalkyl, an optionally substituted C₁-C₆haloheteroalkyl, an optionally substituted C₁-C₆alkenyl, and an optionally substituted C₁-C₆alkynyl;

R¹is selected from hydrogen, halogen, OR⁶, CN, NR⁷R⁸, CH₂OR⁶, CH₂NR⁷R⁸, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆alkenyl, an optionally substituted C₁-C₆alkynyl, an optionally substituted C₁-C₆heteroalkyl, CO₂R⁶, CONR⁷R⁸, SO₃R⁶, and SO₂NR⁷R⁸;

R²and R³are independently selected from hydrogen, halogen, OR⁶, NR⁷R⁸, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆alkenyl, an optionally substituted C₁-C₆alkynyl, and an optionally substituted C₁-C₆heteroalkyl.

Some embodiments include a compound represented by Formula (II):

embedded image

or a salt, ester, amide, or prodrug thereof.

Some embodiments include a compound represented by Formula (III):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

In some embodiments, W is S.

In some embodiments, X is N.

In some embodiments, Y is CR⁹.

In some embodiments, R⁴is selected from the group consisting of pyridyl, pyrazolyl, cyano, triazolyl, and oxazolyl.

In some embodiments, Y is N.

In some embodiments, R⁴is selected from the group consisting of pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, and C₁-C₆alkyl.

Some embodiments include a compound represented by Formula (IV):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein:

In some embodiments, X is N.

Some embodiments include a pharmaceutical composition comprising a compound provided herein and a pharmaceutically acceptable carrier.

Some embodiments include a method of treating a disorder responsive to inhibition of Interleukin-1 Receptor-Associated Kinase-mediated signal transduction comprising administering to a subject in need thereof an effective amount of a compound provided herein.

In some embodiments, the disorder is an inflammatory disorder. In some embodiments, the inflammatory disorder is selected from the group consisting of osteoarthritis, rheumatoid arthritis, multiple sclerosis, corneal ulcers, uveitis, and inflammatory bowel disease.

In some embodiments, the disorder is a skin disorder. In some embodiments, the skin disorder is selected from the group consisting of dermatitis, cutaneous eosinophilias, Lichen planus, urticaria, psoriasis, pruritus, angiodermas, chronic skin ulcers, conjunctivitis, vasculitides, and erythemas.

In some embodiments, the disorder is a respiratory disorder. In some embodiments, the respiratory disorder is selected from the group consisting of asthma, rhinitis, chronic obstructive pulmonary disease, bronchitis, nasal polyposis, nasal congestion, farmer's lung, fibroid lung and cough.

In some embodiments, the disorder is selected from the group consisting of diabetes, obesity, allergic disease, cancer, and sepsis.

Some embodiments include use of a compound provided herein in the preparation of a medicament for treating a disorder responsive to inhibition of Interleukin-1 Receptor-Associated Kinase-mediated signal transduction.

In some embodiments, the disorder is selected from the group consisting of diabetes, obesity, allergic disease, cancer, and sepsis.

Some embodiments include a compound provided herein for treating a disorder responsive to inhibition of Interleukin-1 Receptor-Associated Kinase-mediated signal transduction.

In some embodiments, the disorder is selected from the group consisting of diabetes, obesity, allergic disease, cancer, and sepsis.

DETAILED DESCRIPTION

Some embodiments include a compound of Formula (I):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

custom-character is a single or double bond;

W is selected from CH, CH—CH, O, S, NR⁶, and CO;

Y is N or CR⁹;

Z is N or C, and Z is N if W is CH and Y is CR⁹;

or R⁴and R⁵are linked to form an optionally substituted non-aromatic ring;

A is an optionally substituted aryl or an optionally substituted heteroaryl group;

In some embodiments, if R⁴is pyrazolyl, the pyrazolyl is not substituted with aryl or heteroaryl groups.

In some embodiments, if R⁴is oxazolyl, isoxazolyl, or imidazoyl, the oxazolyl, isoxazolyl, or imidazoyl radical is not substituted with aryl or heteroaryl groups.

Some embodiments include a compound represented by Formula (I-A):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

Some embodiments include a compound represented by Formula (II):

embedded image

or a salt, ester, amide, or prodrug thereof.

Some embodiments include a compound represented by Formula (III):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

In some embodiments, W is S.

In some embodiments, X is N.

In some embodiments, Y is CR⁹.

In some embodiments, R⁴is selected from the group consisting of pyridyl, pyrazolyl, cyano, triazolyl, and oxazolyl.

In some embodiments, Y is N.

In some embodiments, R⁴is selected from the group consisting of pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, and C₁-C₆alkyl.

Some embodiments include a compound represented by Formula (IV):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein:

In some embodiments, X is N.

DEFINITIONS

Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. Standard chemical symbols are used interchangeably with the full names represented by such symbols. Thus, for example, the terms “hydrogen” and “H” are understood to have identical meaning. Standard techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques may be performed e.g., using kits according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference in its entirety for any purpose.

The term “alkyl” refers to a branched or unbranched aliphatic hydrocarbon group. An alkyl may be a “saturated alkyl,” which means that it does not contain any alkene or alkyne groups. An alkyl group may be an “unsaturated alkyl,” which means that it comprises at least one alkene or alkyne group. An alkyl, whether saturated or unsaturated, may be branched or straight chain. Alkyls may be cyclic or non-cyclic. Cyclic alkyls may include multicyclic systems including fused alkyl rings. Alkyls may be substituted or unsubstituted. Alkyls include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, each of which may be optionally substituted.

In certain embodiments, an alkyl comprises 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that an alkyl group may comprise only 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the term “alkyl” also includes instances where no numerical range of carbon atoms is designated).

The term “lower alkyl” refers to an alkyl comprising 1 to 5 carbon atoms. The term “medium alkyl” refers to an alkyl comprising 5 to 10 carbon atoms. An alkyl may be designated as “C₁-C₄alkyl” or similar designations. By way of example only, “C₁-C₄alkyl” indicates an alkyl having one, two, three, or four carbon atoms, e.g., the alkyl is selected from methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.

The term “alkenyl” refers to an alkyl group comprising at least one carbon-carbon double bond, including by way of non-limiting example ethenyl, propenyl, and butenyl.

The term “alkynyl” refers to an alkyl group comprising at least one carbon-carbon triple bond, including by way of non-limiting example ethynyl, propynyl, and butynyl.

The term “haloalkyl” refers to an alkyl in which at least one hydrogen atom is replaced with a halogen atom. In certain of the embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another. In certain of such embodiments, the halogen atoms are not all the same as one another.

The term “heteroalkyl” refers to a branched or unbranched aliphatic hydrocarbon group comprising one or more oxygen, sulfur, nitrogen, or NH. Examples of heteroalkyls include, but are not limited to, CH₃C(═O)CH₂—, CH₃C(═O)CH₂CH₂—, CH₃CH₂C(═O)CH₂CH₂—, CH₃C(═O)CH₂CH₂CH₂—, CH₃NHC(═O)CH₂—, CH₃C(═O)NHCH₂—CH₃OCH₂CH₂—, CH₃NHCH₂—, and the like.

The term “straight-chain alkoxy” refers to a group comprising the formula: —(CH₂)_pO— wherein p is any integer. Straight-chain alkoxy does not include substituted or branched alkoxy groups.

The term “non-straight-chain-alkoxy-heteroalkyl” refers to any heteroalkyl that is not a straight-chain alkoxy heteroalkyl. Thus, for example, non-straight-chain-alkoxy heteroalkyls include, but are not limited to: 2,2-isopropyloxy; 1,2-propyloxy; 1,1-ethyloxy; methylamino; ethylamino; propylamino; methylpyrrolidino; and methylpiperidino.

The term “heterohaloalkyl” refers to a heteroalkyl in which at least one hydrogen atom is replaced with a halogen atom.

The term “carbocycle” refers to a group comprising a covalently closed ring, wherein each of the atoms that forms and/or comprises the ring is a carbon atom. Carbocylic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine carbon atoms. Carbocycles may be optionally substituted.

The term “heterocycle” refers to a group comprising a covalently closed ring wherein at least one atom that forms and/or comprises the ring is a heteroatom. Heterocyclic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Any number of those atoms may be heteroatoms (i.e., a heterocyclic ring may comprise one, two, three, four, five, six, seven, eight, nine, or more than nine heteroatoms). In heterocyclic rings comprising two or more heteroatoms, those two or more heteroatoms may be the same or different from one another. Heterocycles may be optionally substituted. Binding to a heterocycle can be at a heteroatom or via a carbon atom. For example, binding for benzo-fused derivatives, may be via a carbon of the benzenoid ring. Examples of heterocycles include, but are not limited to the following:

embedded image

wherein D, E, F, and G independently represent a heteroatom. Each of D, E, F, and G may be the same or different from one another.

The term “heteroatom” refers to an atom other than carbon or hydrogen. Heteroatoms, typically, are independently selected from oxygen, sulfur, nitrogen, and phosphorus, but heteroatoms are not limited to those atoms. In embodiments in which two or more heteroatoms are present, the two or more heteroatoms may all be the same as one another, or some or all of the two or more heteroatoms may each be different from the others.

The term “aromatic” refers to a group comprising a covalently closed ring having a delocalized π-electron system. Aromatic rings may be formed by five, six, seven, eight, nine, or more than nine atoms. Aromatics may be optionally substituted. Examples of aromatic groups include, but are not limited to phenyl, naphthalenyl, phenanthrenyl, anthracenyl, tetralinyl, fluorenyl, indenyl, and indanyl. The term aromatic includes, for example, benzenoid groups, connected via one of the ring-forming carbon atoms, and optionally carrying one or more substituents selected from an aryl, a heteroaryl, a cycloalkyl, a non-aromatic ring, a halo, a hydroxy, an amino, a cyano, a nitro, an alkylamido, an acyl, a C_1-6alkoxy, a C_1-6alkyl, a C_1-6hydroxyalkyl, a C_1-6aminoalkyl, a C_1-6alkylamino, an alkylsulfenyl, an alkylsulfinyl, an alkylsulfonyl, an sulfamoyl, or a trifluoromethyl. In certain embodiments, an aromatic group is substituted at one or more of the para, meta, and/or ortho positions. Examples of aromatic groups comprising substitutions include, but are not limited to, phenyl, 3-halophenyl, 4-halophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-aminophenyl, 4-aminophenyl, 3-methylphenyl, 4-methylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-trifluoromethoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, dimethylphenyl, naphthyl, hydroxynaphthyl, hydroxymethylphenyl, (trifluoromethyl)phenyl, alkoxyphenyl, 4-morpholin-4-ylphenyl, 4-pyrrolidin-1-ylphenyl, 4-pyrazolylphenyl, 4-triazolylphenyl, and 4-(2-oxopyrrolidin-1-yl)phenyl.

The term “aryl” refers to an aromatic group wherein each of the atoms forming the ring is a carbon atom. Aryl rings may be formed by five, six, seven, eight, nine, or more than nine carbon atoms. Aryl groups may be optionally substituted.

The term “heteroaryl” refers to an aromatic group wherein at least one atom forming the aromatic ring is a heteroatom. Heteroaryl rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Heteroaryl groups may be optionally substituted. Examples of heteroaryl groups include, but are not limited to, aromatic C_3-8heterocyclic groups comprising one oxygen or sulfur atom or up to four nitrogen atoms, or a combination of one oxygen or sulfur atom and up to two nitrogen atoms, and their substituted as well as benzo- and pyrido-fused derivatives, for example, connected via one of the ring-forming carbon atoms. In certain embodiments, heteroaryl groups are optionally substituted with one or more substituents, independently selected from halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, C_1-6-alkoxy, C_1-6-hydroxyalkyl, C_1-6-aminoalkyl, C_1-6-alkylamino, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, sulfamoyl, or trifluoromethyl. Examples of heteroaryl groups include, but are not limited to, unsubstituted and mono- or di-substituted derivatives of furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, indole, oxazole, benzoxazole, isoxazole, benzisoxazole, thiazole, benzothiazole, isothiazole, imidazole, benzimidazole, pyrazole, indazole, tetrazole, quinoline, isoquinoline, pyridazine, pyrimidine, purine, pyrazine, furazan, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, triazole, benzotriazole, pteridine, phenoxazole, oxadiazole, benzopyrazole, quinolizine, cinnoline, phthalazine, quinazoline, and quinoxaline. In some embodiments, the substituents are halo, hydroxy, cyano, C_1-6-alkyl, hydroxy-C_1-6-alkyl, and amino-C_1-6-alkyl.

The term “non-aromatic ring” refers to a group comprising a covalently closed ring that does not have a delocalized π-electron system in its principle and/or predominant tautomer.

The term “cycloalkyl” refers to a group comprising a non-aromatic ring wherein each of the atoms forming the ring is a carbon atom. Cycloalkyl rings may be formed by three, four, five, six, seven, eight, nine, or more than nine carbon atoms. Cycloalkyls may include multicyclic systems (e.g., fused ring systems). Cycloalkyls may be optionally substituted. In certain embodiments, a cycloalkyl comprises one or more unsaturated bonds. Examples of cycloalkyls include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, and cycloheptene.

The term “non-aromatic ring” refers to a group comprising a non-aromatic ring moiety wherein the atoms that form and/or comprise the ring include carbon and/or heteroatoms. When heteroatoms are included in the ring, one or more such heteroatoms may be present. Non-aromatic rings also optionally include one or more carbonyl or thiocarbonyl groups as part of the ring. Non-aromatic rings may be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Non-aromatic rings may be optionally substituted. Examples of non-aromatic rings include, but are not limited to, cycloalkyls (including but not limited to cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, and cycloheptene), lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, tetrahydrothiopyran, 4H-pyran, tetrahydropyran, piperidine, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, pyrrolidone, pyrrolidione, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, and 1,3-oxathiolane.

The term “arylalkyl” refers to a group comprising an aryl group bound to an alkyl group.

The term “ring” refers to any covalently closed structure. Rings include, for example, carbocycles (e.g., aryls and cycloalkyls), heterocycles (e.g., heteroaryls and non-aromatic heterocyclic rings), aromatics (e.g., aryls and heteroaryls), and non-aromatic rings. Rings may be optionally substituted. Rings may form part of a ring system.

The term “ring system” refers to a either a single ring or two or more rings, wherein, if two or more rings are present, the two or more of the rings are fused. The term “fused” refers to structures in which two or more rings share one or more bonds.

The substituent “R” appearing by itself and without a number designation refers to a substituent selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and non-aromatic ring (bonded through a ring carbon).

The term “O-carboxy” refers to the group consisting of formula RC(═O)O—.

The term “C-carboxy” refers to the group consisting of formula —C(═O)OR.

The term “acetyl” refers to the group consisting of formula —C(═O)CH₃.

The term “trihalomethanesulfonyl” refers to the group consisting of formula X₃CS(═O)₂— where X is a halogen.

The term “cyano” refers to the group consisting of formula —CN.

The term “isocyanato” refers to the group consisting of formula —NCO.

The term “thiocyanato” refers to the group consisting of formula —CNS.

The term “isothiocyanato” refers to the group consisting of formula —NCS.

The term “sulfonyl” refers to the group consisting of formula —S(═O)—R.

The term “S-sulfonamido” refers to the group consisting of formula —S(═O)₂NR.

The term “N-sulfonamido” refers to the group consisting of formula RS(═O)₂NH—.

The term “trihalomethanesulfonamido” refers to the group consisting of formula X₃CS(═O)₂NR—.

The term “O-carbamyl” refers to the group consisting of formula —OC(═O)—NR.

The term “N-carbamyl” refers to the group consisting of formula ROC(═O)NH—.

The term “O-thiocarbamyl” refers to the group consisting of formula —OC(═S)—NR.

The term “N-thiocarbamyl” refers to the group consisting of formula ROC(═S)NH—.

The term “C-amido” refers to the group consisting of formula —C(═O)—NR₂.

The term “N-amido” refers to the group consisting of formula RC(═O)NH—.

The term “oxo” refers to the group consisting of formula ═O.

The term “carbonyl” refers to the group consisting of formula C(═O)R.

The term “thiocarbonyl” refers to the group consisting of formula C(═S)R.

The term “dihydropyrazolylene” refers to a di-radical of an optionally substituted dihydropyrazole ring, wherein the dihydropyrazole ring has the structure:

embedded image

and wherein the two radicals may be at any positions on the ring.

The term “pyrazolyl” refers to a radical of a pyrazole ring, wherein the pyrazole ring has the structure:

embedded image

and wherein the radical may be at any position on the ring.

The term “ester” refers to a chemical moiety with formula —(R)_n—COOR′, where R and R′ are independently selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and non-aromatic ring (bonded through a ring carbon), where n is 0 or 1.

The term “amide” refers to a chemical moiety with formula —(R)_n—C(O)NHR′ or —(R)_n—NHC(O)R′, where R and R′ are independently selected from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), where n is 0 or 1. In certain embodiments, an amide may be an amino acid or form part of a peptide.

The terms “amine,” “hydroxy,” and “carboxyl” include such groups that have been esterified or amidified. Procedures and specific groups used to achieve esterification and amidification are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3^rdEd., John Wiley & Sons, New York, N.Y., 1999, which is incorporated herein in its entirety.

Unless otherwise indicated, the term “optionally substituted” refers to a group in which none, one, or more than one of the hydrogen atoms has been replaced with one or more group(s) individually and independently selected from: alkyl, heteroalkyl, haloalkyl, alkenyl, alkynyl, heterohaloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic ring, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, oxo, and amino, including mono- and di-substituted amino groups, and the protected derivatives of amino groups. Such protective derivatives (and protecting groups that may form such protective derivatives) are known to those of skill in the art and may be found in references such as Greene and Wuts, above. In embodiments in which two or more hydrogen atoms have been substituted, the substituent groups may together form a ring.

Throughout the specification, groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.

The term “carrier” refers to a compound that facilitates the incorporation of another compound into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier for improving incorporation of certain organic compounds into cells or tissues.

The term “pharmaceutical agent” refers to a chemical compound or composition capable of inducing a desired therapeutic effect in a patient. In certain embodiments, a pharmaceutical agent comprises an active agent, which is the agent that induces the desired therapeutic effect. In certain embodiments, a pharmaceutical agent comprises a prodrug. In certain embodiments, a pharmaceutical agent comprises inactive ingredients such as carriers, excipients, and the like.

The term “therapeutically effective amount” refers to an amount of a pharmaceutical agent sufficient to achieve a desired therapeutic effect.

The term “prodrug” refers to a pharmaceutical agent that is converted from a less active form into a corresponding more active form in vivo.

The term “pharmaceutically acceptable” refers to a formulation of a compound that does not significantly abrogate the biological activity, a pharmacological activity and/or other properties of the compound when the formulated compound is administered to a patient. In certain embodiments, a pharmaceutically acceptable formulation does not cause significant irritation to a patient.

The term “co-administer” refers to administering more than one pharmaceutical agent to a patient. In certain embodiments, co-administered pharmaceutical agents are administered together in a single dosage unit. In certain embodiments, co-administered pharmaceutical agents are administered separately. In certain embodiments, co-administered pharmaceutical agents are administered at the same time. In certain embodiments, co-administered pharmaceutical agents are administered at different times.

The term “patient” includes human and animal subjects.

The term “substantially pure” means an object species (e.g., compound) is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition). In certain embodiments, a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all species present. In certain embodiments, a substantially pure composition will comprise more than about 80%, 85%, 90%, 95%, or 99% of all species present in the composition. In certain embodiments, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single species.

Certain Compounds

In certain embodiments, compounds of Formula (I) are provided:

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

custom-character is a single or double bond;

W is selected from CH, CH—CH, O, S, NR⁶, and CO;

Y is N or CR⁹;

Z is N or C, and Z is N if W is CH and Y is CR⁹;

or R⁴and R⁵are linked to form an optionally substituted non-aromatic ring;

A is an optionally substituted aryl or an optionally substituted heteroaryl group;

In some embodiments, if R⁴is pyrazolyl, the pyrazolyl is not substituted with aryl or heteroaryl groups.

In some embodiments, if R⁴is oxazolyl, isoxazolyl, or imidazoyl, the oxazolyl, isoxazolyl, or imidazoyl radical is not substituted with aryl or heteroaryl groups.

Some embodiments include a compound represented by Formula (I-A):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein

Some embodiments include a compound represented by Formula (II), (III), or (IV):

embedded image

or a salt, ester, amide, or prodrug thereof,

wherein:

W is selected from O, S, NR⁶, and CO;

X is N or CR⁵;

Y is N or CR⁹;

each R⁵is independently selected from hydrogen, halogen, OR⁶, an optionally substituted C₁-C₆alkyl, an optionally substituted C₁-C₆haloalkyl, an optionally substituted C₁-C₆heteroalkyl, an optionally substituted C₁-C₆haloheteroalkyl, an optionally substituted C₁-C₆alkenyl, and an optionally substituted C₁-C₆alkynyl;

or R⁴and R⁵are linked to form an optionally substituted non-aromatic ring;

each R⁶is independently selected from hydrogen, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted C₁-C₁₀alkyl, an optionally substituted C₁-C₁₀haloalkyl, and an optionally substituted C₁-C₁₀heteroalkyl, each optionally fused with a substituted aryl or a substituted heteroaryl;

each R⁷and R⁸is independently selected from hydrogen, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted C₁-C₁₀alkyl, an optionally substituted C₁-C₁₀haloalkyl, an optionally substituted C₁-C₁₀alkenyl, an optionally substituted C₁-C₁₀alkynyl, and an optionally substituted C₁-C₁₀heteroalkyl, each optionally fused with a substituted aryl or a substituted heteroaryl, or R⁷and R⁸are linked to form an optionally substituted non-aromatic ring;

A is an optionally substituted aryl or an optionally substituted heteroaryl group;

In some embodiments, if R⁴is a pyrazolyl, oxazolyl, isoxazolyl, or imidazoyl radical in compounds of Formula (II), (III), or (IV), the pyrazolyl, oxazolyl, isoxazolyl, or imidazoyl radical is not substituted with aryl or heteroaryl groups.

In some specific embodiments, if R⁴is a pyrazolyl radical in compounds of Formula (II), (III), or (IV), the pyrazolyl is not substituted with aryl or heteroaryl groups.

Certain Synthetic Methods

In certain embodiments, compounds of the present invention can by synthesized using the following Schemes.

embedded image

Scheme I describes the synthesis of aminopyridine substituted benzothiazoles. An aminopyridine 1 is treated with a base such as NaH and reacted with 6-bromo-2-chlorobenzothiazole 2 to afford compounds of structure 3. Palladium catalyzed coupling of structure 3 with a boronic acid affords compounds of structure 4.

embedded image

Scheme II describes the synthesis of aminopyridine substituted benzothiazoles. Aminopyridine 1 is converted to an isothiocyanate 5 and reacted with an aniline 6, to give a thiourea 7. The thiourea is oxidatively cyclized with, for example, bromine to give the benzothiazole 4.

embedded image

Scheme III describes the synthesis of aminopyridine substituted imidazopyridines 10. A 2-halopyridine, such as compound 8, is coupled with an aminoimidazopyridine, such as 9, under the influence of a palladium catalyst and a base to furnish products 10.

One of skill in the art will recognize that analogous synthetic schemes may be used to synthesize similar compounds. One of skill will recognize that compounds of the present invention may be synthesized using other synthesis schemes. In certain embodiments, the invention provides a salt corresponding to any of the compounds provided herein.

Certain Pharmaceutical Agents

Some embodiments include pharmaceutical agents. In some embodiments a pharmaceutical agent can include a compound and/or composition provided herein and a pharmaceutical carrier. In certain embodiments, at least one compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt, ester, amide, and/or prodrug thereof, either alone or combined with one or more pharmaceutically acceptable carriers, forms a pharmaceutical agent. Techniques for formulation and administration of compounds of the present embodiments may be found for example, in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., 18th edition, 1990, which is incorporated herein by reference in its entirety.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is prepared using known techniques, including, but not limited to mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting processes.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is a liquid (e.g., a suspension, elixir and/or solution). In certain of such embodiments, a liquid pharmaceutical agent comprising one or more compounds of the present embodiments is prepared using ingredients known in the art, including, but not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is a solid (e.g., a powder, tablet, and/or capsule). In certain of such embodiments, a solid pharmaceutical agent comprising one or more compounds of the present embodiments is prepared using ingredients known in the art, including, but not limited to, starches, sugars, diluents, granulating agents, lubricants, binders, and disintegrating agents.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is formulated as a depot preparation. Certain such depot preparations are typically longer acting than non-depot preparations. In certain embodiments, such preparations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, depot preparations are prepared using suitable polymeric or hydrophobic materials (for example an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical agents including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises one or more tissue-specific delivery molecules designed to deliver the pharmaceutical agent to specific tissues or cell types. For example, in certain embodiments, pharmaceutical agents include liposomes coated with a tissue-specific antibody.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises a co-solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™, and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises a sustained-release system. A non-limiting example of such a sustained-release system is a semi-permeable matrix of solid hydrophobic polymers. In certain embodiments, sustained-release systems may, depending on their chemical nature, release compounds over a period of hours, days, weeks or months.

Certain compounds used in pharmaceutical agent of the present embodiments may be provided as pharmaceutically acceptable salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments comprises an active ingredient in a therapeutically effective amount. In certain embodiments, the therapeutically effective amount is sufficient to prevent, alleviate or ameliorate symptoms of a disease or to prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is formulated as a prodrug. In certain embodiments, prodrugs are useful because they are easier to administer than the corresponding active form. For example, in certain instances, a prodrug may be more bioavailable (e.g., through oral administration) than is the corresponding active form. In certain instances, a prodrug may have improved solubility compared to the corresponding active form. In certain embodiments, a prodrug is an ester. In certain embodiments, such prodrugs are less water soluble than the corresponding active form. In certain instances, such prodrugs possess superior transmittal across cell membranes, where water solubility is detrimental to mobility. In certain embodiments, the ester in such prodrugs is metabolically hydrolyzed to carboxylic acid. In certain instances the carboxylic acid containing compound is the corresponding active form. In certain embodiments, a prodrug comprises a short peptide (polyaminoacid) bound to an acid group. In certain of such embodiments, the peptide is metabolized to form the corresponding active form.

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is useful for treating a condition or disorder in a mammal, such as a human. Suitable administration routes include, but are not limited to, oral, rectal, transmucosal, intestinal, enteral, topical, suppository, through inhalation, intrathecal, intraventricular, intraperitoneal, intranasal, intraocular and parenteral (e.g., intravenous, intramuscular, intramedullary, and subcutaneous). In certain embodiments, pharmaceutical intrathecals are administered to achieve local rather than systemic exposures. For example, pharmaceutical agents may be injected directly in the area of desired effect (e.g., in the renal or cardiac area).

In certain embodiments, a pharmaceutical agent comprising one or more compounds of the present embodiments is administered in the form of a dosage unit (e.g., tablet, capsule, bolus, etc.). In certain embodiments, such dosage units comprise a compound or composition provided herein, such as a compound or composition comprising Formula (I), (II), (III), or (IV), in a dose from about 1 μg/kg of body weight to about 50 mg/kg of body weight, and from about 2 μg/kg of body weight to about 25 mg/kg of body weight, from about 10 μg/kg of body weight to about 5 mg/kg of body weight. In certain embodiments, pharmaceutical agents are administered as needed, once per day, twice per day, three times per day, or four or more times per day. It is recognized by those skilled in the art that the particular dose, frequency, and duration of administration depends on a number of factors, including, without limitation, the biological activity desired, the condition of the patient, and tolerance for the pharmaceutical agent.

In certain embodiments, a pharmaceutical agent comprising a compound of the present embodiments is prepared for oral administration. In certain of such embodiments, a pharmaceutical agent is formulated by combining one or more compounds of the present embodiments with one or more pharmaceutically acceptable carriers. Certain of such carriers enable compounds of the present embodiments to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. In certain embodiments, pharmaceutical agents for oral use are obtained by mixing one or more compounds of the present embodiments and one or more solid excipient. Suitable excipients include, but are not limited to, fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certain embodiments, such a mixture is optionally ground and auxiliaries are optionally added. In certain embodiments, pharmaceutical agents are formed to obtain tablets or dragee cores. In certain embodiments, disintegrating agents (e.g., cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate) are added.

In certain embodiments, dragee cores are provided with coatings. In certain of such embodiments, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to tablets or dragee coatings.

In certain embodiments, pharmaceutical agents for oral administration are push-fit capsules made of gelatin. Certain of such push-fit capsules comprise one or more compounds of the present embodiments in admixture with one or more filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In certain embodiments, pharmaceutical agents for oral administration are soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In certain soft capsules, one or more compounds of the present embodiments are be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

In certain embodiments, pharmaceutical agents are prepared for buccal administration. Certain of such pharmaceutical agents are tablets or lozenges formulated in conventional manner.

In certain embodiments, a pharmaceutical agent is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical agent comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical agents for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical agents for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical agents for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, such suspensions may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

In certain embodiments, a pharmaceutical agent is prepared for transmucosal administration. In certain of such embodiments penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

In certain embodiments, a pharmaceutical agent is prepared for administration by inhalation. Certain of such pharmaceutical agents for inhalation are prepared in the form of an aerosol spray in a pressurized pack or a nebulizer. Certain of such pharmaceutical agents comprise a propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In certain embodiments using a pressurized aerosol, the dosage unit may be determined with a valve that delivers a metered amount. In certain embodiments, capsules and cartridges for use in an inhaler or insufflator may be formulated. Certain of such formulations comprise a powder mixture of a compound of the present embodiments and a suitable powder base such as lactose or starch.

In certain embodiments, a pharmaceutical agent is prepared for rectal administration, such as a suppositories or retention enema. Certain of such pharmaceutical agents comprise known ingredients, such as cocoa butter and/or other glycerides.

In certain embodiments, a pharmaceutical agent is prepared for topical administration. Certain of such pharmaceutical agents comprise bland moisturizing bases, such as ointments or creams. Exemplary suitable ointment bases include, but are not limited to, petrolatum, petrolatum plus volatile silicones, lanolin and water in oil emulsions such as Eucerin™, available from Beiersdorf (Cincinnati, Ohio). Exemplary suitable cream bases include, but are not limited to, Nivea™ Cream, available from Beiersdorf (Cincinnati, Ohio), cold cream (USP), Purpose Cream™, available from Johnson & Johnson (New Brunswick, N.J.), hydrophilic ointment (USP) and Lubriderm™, available from Pfizer (Morris Plains, N.J.).

In certain embodiments, the formulation, route of administration and dosage for a pharmaceutical agent of the present embodiments can be chosen in view of a particular patient's condition. In certain embodiments, a pharmaceutical agent is administered as a single dose. In certain embodiments, a pharmaceutical agent is administered as a series of two or more doses administered over one or more days.

In certain embodiments, a pharmaceutical agent of the present embodiments is administered to a patient between about 0.1% and 500%, 5% and 200%, 10% and 100%, 15% and 85%, 25% and 75%, or 40% and 60% of an established human dosage. Where no human dosage is established, a suitable human dosage may be inferred from ED₅₀or ID₅₀values, or other appropriate values derived from in vitro or in vivo studies.

In certain embodiments, a daily dosage regimen for a patient comprises an oral dose of between 0.1 mg and 2000 mg, 5 mg and 1500 mg, 10 mg and 1000 mg, 20 mg and 500 mg, 30 mg and 200 mg, or 40 mg and 100 mg of a compound of the present embodiments. In certain embodiments, a daily dosage regimen is administered as a single daily dose. In certain embodiments, a daily dosage regimen is administered as two, three, four, or more than four doses.

In certain embodiments, a pharmaceutical agent of the present embodiments is administered by continuous intravenous infusion. In certain of such embodiments, from 0.1 mg to 500 mg of a composition of the present embodiments is administered per day.

In certain embodiments, a pharmaceutical agent of the present embodiments is administered for a period of continuous therapy. For example, a pharmaceutical agent of the present embodiments may be administered over a period of days, weeks, months, or years.

Dosage amount, interval between doses, and duration of treatment may be adjusted to achieve a desired effect. In certain embodiments, dosage amount and interval between doses are adjusted to maintain a desired concentration of compound in a patient. For example, in certain embodiments, dosage amount and interval between doses are adjusted to provide plasma concentration of a compound of the present embodiments at an amount sufficient to achieve a desired effect. In certain of such embodiments the plasma concentration is maintained above the minimal effective concentration (MEC). In certain embodiments, pharmaceutical agents of the present embodiments are administered with a dosage regimen designed to maintain a concentration above the MEC for 10-90% of the time, between 30-90% of the time, or between 50-90% of the time.

In certain embodiments in which a pharmaceutical agent is administered locally, the dosage regimen is adjusted to achieve a desired local concentration of a compound of the present embodiments.

In certain embodiments, a pharmaceutical agent may be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound of the present embodiments formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

In certain embodiments, a pharmaceutical agent is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

Certain Therapeutic Methods

Some compounds and compositions provided herein, such as compounds and/or compositions comprising Formula (I), (II), (III), and (IV) are useful for the treatment of a variety of diseases and disorders. Examples of diseases and disorders include inflammatory disorders, cell proliferative disorders, and immune-related disorders, and disorders associated with IRAK-mediated signal transduction.

Inflammation of tissues and organs occurs in a wide range of disorders and diseases and in certain variations results from activation of the cytokine family of receptors. Example inflammatory disorders associated with activation of IRAK kinases and/or disorders IRAK-mediated signal transduction include skin disorders, respiratory disorders, and other disorders with an allergic component. These disorders are treated or prevented by modulation of IRAK activity, for example, by administration of certain compounds and/or compositions provided herein. In some embodiments, methods of treating a subject in need thereof include administering an effective amount of a compound or composition provided herein. Some embodiments include treating a disorder responsive to inhibition of IRAK-mediated signal transduction.

Example skin disorders include dermatitis, cutaneous eosinophilias, Lichen planus, urticaria, psoriasis, pruritus, angiodermas, chronic skin ulcers, conjunctivitis, vasculitides, or erythemas. Examples of respiratory disorders include asthma, rhinitis, chronic obstructive pulmonary disease, bronchitis, nasal polyposis, nasal congestion, farmer's lung, fibroid lung and cough. Other example diseases that may be treated with the compounds and compositions provided herein include osteoarthritis, rheumatoid arthritis, multiple sclerosis, corneal ulcers, uveitis, pain and inflammatory bowel disease. More example disorders include diabetes, obesity, allergic disease, cancer, and sepsis.

In some embodiments, the compounds and compositions provided herein can be administered in combination with an additional active agent. Examples of other active agents include anti-inflammatory agents, analgesic agents, such as: opiate agonists; lipoxygenase inhibitors; cyclooxygenase inhibitors, such as cyclooxygenase-2 inhibitors; interleukin inhibitors, such as interleukin-1 receptor antagonist; NMDA antagonists; inhibitors of nitric oxide or inhibitors of the synthesis of nitric oxide; a non-steroidal anti-inflammatory agent; or a cytokine-suppressing anti-inflammatory agent, for example with a compound such as acetaminophen, aspirin, codeine, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sulindac, tenidap, and the like. In some embodiments, the instant compounds and/or composition may be administered with: a potentiator such as caffeine, an H2-antagonist (e.g., ranitidine), simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a sedating or non-sedating antihistamine.

More examples of additional active agents include (a) VLA-4 antagonists; (b) corticosteroids, such as beclomethasone, methylprednisolone, betamethasone, prednisone, prednisolone, dexamethasone, fluticasone and hydrocortisone, and corticosteroid analogs such as budesonide; (c) immunosuppressants such as cyclosporine (cyclosporine A, Sandimmune®, Neoral®), tacrolimus (FK-506, Prograf®), rapamycin (sirclimus, Rapamune®) and other FK-506 type immunosuppressants, and mycophenolate, e.g., mycophenolate mofetil (CellCept®); (d) antihistamines (H1-histamine antagonists) such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (e) non-steroidal anti-asthmatics such as β2-agonists (e.g., terbutaline, metaproterenol, fenoterol, isoetharine, albuterol, bitolterol and pirbuterol), theophylline, cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists (e.g., zafirlukast, montelukast, pranlukast, iralukast, pobilukast and SKB-106,203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005); (f) non-steroidal antiinflammatory agents (NSAIDs) such as propionic acid derivatives (e.g., alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid and tioxaprofen), acetic acid derivatives (e.g., indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin and zomepirac), fenamic acid derivatives (e.g., flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivative (e.g., diflunisal and flufenisal), oxicams (e.g., isoxicam, piroxicam, sudoxicam and tenoxican), salicylates (e.g., acetyl salicylic acid, sulfasalazine and analogs, mesalamine) and the pyrazolones (e.g., apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone and phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Celebrex®) and rofecoxib (Vioxx®); (h) inhibitors of phosphodiesterase type IV (PDE-IV); (i) interleukin inhibitors, such as interleukin-I (IL-I) inhibitors, and chemokine receptor antagonists; j) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin and other statins), bile acid sequestrants (e.g., cholestyramine and colestipol), nicotinic acid (niacin), fibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), probucol and nitroglycerin; (k) anti-diabetic agents such as insulin, sulfonylureas (e.g., glyburide, meglinatide), biguanides, e.g., metformin (Glucophage®), α-glucosidase inhibitors (acarbose), thiazolidinone compounds, e.g., rosiglitazone (Avandia®), troglitazone (Rezulin®) and pioglitazone (Actos®); (l) preparations of interferon beta (interferon β-1α, interferon β-1β); (m) gold compounds such as auranofin and aurothioglucose, (n) etanercept (Enbrel®), (o) antibody therapies such as orthoclone (OKT3), daclizumab (Zenapax®), basiliximab (Simulect®), infliximab (Remicade®) and D2E6 TNF antibody, (p) lubricants or emollients such as petrolatum and lanolin, (q) keratolytic agents, (r) vitamin D3 derivatives, e.g., calcipotriene or calcipotriol (Dovonex®), (s) PUVA, (t) anthralin (Drithrocreme®), (u) etretinate (Tegison®) and isotretinoin, (v) multiple sclerosis therapeutic agents such as β-1β (Betaseron®), interferon β-1α (Avonex®), azathioprine (Imurek®, Imuran®), glatiramer acetate (Capoxone®), a glucocorticoid (e.g., prednisolone) and cyclophosphamide and (w) β3 adrenergic receptor agonists, leptin or derivatives thereof, and neuropeptide Y (e.g., NPY5) antagonists; (x) other compounds such as 5-aminosalicylic acid and prodrugs thereof; (y) DNA-alkylating agents (e.g., cyclophosphamide, ifosfamide), antimetabolites (e.g., azathioprene, 6-mercaptopurine, methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist), microtubule disruptors (e.g., vincristine, vinblastine, paclitaxel, colchicine, nocodazole and vinorelbine), DNA intercalators (e.g., doxorubicin, daunomycin and cisplatin), DNA synthesis inhibitors such as hydroxyurea, DNA cross-linking agents, e.g., mitomycin C, and hormone therapy (e.g., tamoxifen, and flutamide).

In still other particular embodiments, compounds and compositions provided herein are administered for the treatment of rheumatoid arthritis, wherein the compounds are administered either alone or in combination with a second therapeutic agent selected from methotrexate, sulfasalazine, a COX-2 inhibitor, hydroxychloroquine, cyclosporine A, D-penicillamine, infliximab, etanercept, auranofin and aurothioglucose.

In yet other particular embodiments, the present compounds are administered for the treatment of inflammatory bowel disease wherein the compound of the invention is used alone or in combination with a second therapeutic agent selected from sulfasalazine and analogs (e.g., olsalazine) mesalamine, corticosteroids (e.g., prednisone, prednisolone) and analogs (e.g., budesonide), azathioprine, 6-mercaptopurine, cyclosporine A, methotrextate, infliximab, or an IL-1 inhibitor.

In other particular embodiments, the present methods are directed to the treatment of multiple sclerosis using a compound of the invention either alone or in combination with a second therapeutic agent selected from interferon β-1β, interferon β-1α, azathioprine, glatiramer acetate, a glucocorticoid (e.g., prednisolone), and cyclophosphamide.

EXAMPLES

The following examples, including experiments and results achieved, are provided for illustrative purposes only and are not to be construed as limiting the present invention. Where chemical structures depict atoms having an unfilled valency, it is to be understood that the valency is satisfied with one or more hydrogen atoms.

Example 1
Synthesis of N-(4-hydroxymethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine (Compound 101, Structure 4 in Scheme I, R¹═CH₂OH, R⁴=4-pyridyl)

embedded image

To a solution of 4-(((tert-butyldimethylsilypoxy)methyl)pyridin-2-amine (1.92 g, 8.0 mmol, 1 eq.) in anhydrous tetrahydrofuran (THF) (100 mL) was added NaH (2.25 g, 56.0 mmol, 7.0 eq) at 0° C., after stirring at room temperature for 30 min, a solution of 6-bromo-2-chlorobenzo[d]thiazole (2.0 g, 8.1 mmol, 1 eq) in THF (20 mL) was added dropwise. Then the reaction mixture was heated to 65° C. for 2 hours. After cooling, water was added, the organic layer was separated and the aqueous was extracted with EtOAc, dried and concentrated to give 6-bromo-N-(4-(((tert-butyldimethylsilypoxy)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine (1.5 g, 37%) which was used directly without further purification. ¹H NMR (500 MHz, CDCl₃) δ 8.03 (d, J=9.0, 1H); 6.87 (d, J=2.6, 1H); 6.64 (dd, J=9.0, 2.6, 1H); 4.58 (t, J=5.2, 1H); 3.67 (s, 3H); 3.21 (td, J=7.1, 5.2, 2H); 2.31 (t, J=7.5, 2H); 1.70-1.59 (m, 4H); 1.46-1.29 (m, 10H).

embedded image

To a 10 mL microwave tube was added 6-bromo-N-(4-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine (400 mg, 1.03 mmol), pyridine-4-boronic acid (185 mg, 1.5 eq), K₂CO₃(425 mg, 3.09 mmol, 3 eq), Pd(dppf)Cl₂, (25 mg, 0.03 mmol, 0.03 eq), LiCl (130 mg, 3.09 mmol, 3 eq) and 3 mL of dioxane/H₂O (4:1). The mixture was stirred at 140° C. under microwave condition for 1 h. After cooling to room temperature (rt), the mixture was concentrated in vacuo and the residue was purified by flash chromatography to give 125 mg of N-(4-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine.

embedded image

N-(4-(((Tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine (1.8 g, 3.34 mmol, 1 eq.) was dissolved in 6 N HCl/MeOH (30 mL), and the suspension was stirred at room temperature for 2 hours. After completion of the reaction, the solvent was evaporated and the residue was purified by chromatography to give 1.2 g of N-(4-(hydroxymethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine 101. ¹H NMR (DMSO-d₆, 400 MHz) δ 8.95 (d, 2H), 8.75 (s, 1H), 8.45 (d, 2H), 8.35 (d, 1H), 8.11 (d, 1H), 7.84 (d, 1H), 7.22 (s, 1H), 7.00 (d, 1H), 4.60 (s, 2H). MS (ES-API): MH⁺=335.0. HPLC t_R=2.20 min.

Example 2
Synthesis of 6-(pyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine (Compound 102, Structure 4 in Scheme I, R¹═CH₂-pyrrolidin-1-yl, R⁴=4-pyridyl)

embedded image

(2-((6-(Pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methanol 101 (0.12 g, 0.36 mmol, 1 eq.) was dissolved in POCl3 (3 mL) under N2, and the suspension was stirred at 110° C. for 2 hours. After cooling, POCl3 was evaporated under reduced pressure and the residue was basified with sat. Na2CO3 solution, then extracted with DCM, dried and concentrated in vacuo to afford N-(4-(chloromethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine (80 mg, 63%) which was used directly in the next step.

embedded image

A solution of N-(4-(chloromethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine (80 mg, 0.23 mmol, 1 eq.) in 1 mL dioxane was treated with 15 mg of pyrrolidine and 20 mg DIEA. The reaction mixture was stirred at 140° C. under microwave condition for 1 h. After cooling to rt, the mixture was concentrated in vacuo. The residue was washed with EtOH to afford 6-(pyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine 102 without further purification (67 mg). ¹HNMR (CD₃OD, 400 MHz) δ 8.83 (d, 2H), 8.60 (m, 1H), 8.54 (m, 1H), 8.46 (m, 2H), 8.10 (m, 1H), 7.92 (d, 1H), 7.52 (s, 1H), 3.37 (d, 1H), 4.53 (s, 2H), 3.62 (br s, 2H), 3.25 (m, 2H overlapping with signal from CD₃OD), 2.22 (m, 2H), 2.09 (m, 2H). MS (ES-API): MH⁺=388.1. HPLC t_R=2.16 min.

Examples 3-332

Compounds 103-439 were prepared in a similar fashion as described in Examples 1-2 and their structures, names, and found molecular mass ion numbers are summarized in Table 1 (Example: E.g.; Compound: Cmpd).

TABLE 1

E.g.
Structure
Cmpd
Name
[M + H]⁺

3

embedded image

103
6-(1H-pyrazol-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
377.1

4

embedded image

104
N-(4-(piperazin-1- ylmethyl)pyridin-2-yl)-6-(pyridin- 4-yl)benzo[d]thiazol-2-amine
403.1

5

embedded image

105
1-(4-((2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)piperazin-1- yl)ethanone
445.1

6

embedded image

106
1-(4-methylpiperazin-1-yl)-2-(2- ((6-(pyridin-4-yl)benzo[d]thiazol- 2-yl)amino)pyridin-4-yl)ethanone
445.1

7

embedded image

107
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-(pyrrolidin-1-ylmethyl)pyridin- 2-yl)benzo[d]thiazol-2-amine
391.1

8

embedded image

108
5-(1H-pyrazol-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
378.1

9

embedded image

109
N-(4-morpholinopyridin-2-yl)-6- (1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
379.1

10

embedded image

110
N-(4-morpholinopyridin-2-yl)-5- (1H-pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
380.1

11

embedded image

111
(2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)methanol
324.0

12

embedded image

112
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
437.1

13

embedded image

113
N-(4- ((dimethylamino)methyl)pyridin- 2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
352.0

14

embedded image

114
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
448.1

15

embedded image

115
N-(4-(isopropoxymethyl)pyridin- 2-yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
366.0

16

embedded image

116
N-(4-((4-(2- methoxyethyl)piperazin-1- yl)methyl)pyridin-2-yl)-5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
462.2

17

embedded image

117
N-(4-((4-(2- methoxyethyl)piperazin-1- yl)methyl)pyridin-2-yl)-5-(1H- pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
451.2

18

embedded image

118
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(5-methyl-1H- pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
451.2

19

embedded image

119
N-(4-((4-(2- methoxyethyl)piperazin-1- yl)methyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
465.2

20

embedded image

120
2-methoxy-1-(4-(2-((5-(pyridin- 4-yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
462.1

21

embedded image

121
N-(4-(4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
468.1

22

embedded image

122
2-methoxy-1-(4-((2-((5-(pyridin- 4-yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4- yl)methyl)piperazin-1- yl)ethanone
476.2

23

embedded image

123
2-methoxy-1-(4-(2-((6-(pyridin- 4-yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
461.1

24

embedded image

124
N-(4-((4- (methylsulfonyl)piperazin-1- yl)methyl)pyridin-2-yl)-5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
482.1

25

embedded image

125
(S)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
419.1

26

embedded image

126
(R)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
419.1

27

embedded image

127
N-(4-(isopropoxymethyl)pyridin- 2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
377.2

28

embedded image

128
N-(4-(isopropoxymethyl)- pyridin-2-yl)-5-(5-methyl-1H- pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
381.1

29

embedded image

129
(S)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
402.1

30

embedded image

130
N-(4-(isopropoxymethyl)pyridin- 2-yl)-5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
378.1

31

embedded image

131
5-(1H-pyrazol-4-yl)-N-(4-(4- (3,3,3-trifluoropropyl)piperazin- 1-yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
475.2

32

embedded image

132
N-(4-(4- (isopropylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(1H-pyrazol- 4-yl)thiazolo[5,4-b]pyridin-2- amine
485.1

33

embedded image

133
N-(4-(4- (isopropylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
496.0

34

embedded image

134
2-methoxy-1-(4-(2-((5- (pyrimidin-5-yl)thiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)ethanone
463.1

35

embedded image

135
N-(4-(4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyrimidin-5- yl)thiazolo[5,4-b]pyridin-2- amine
469.1

36

embedded image

136
2-((6-methyl-4-(pyrrolidin-3- ylamino)pyridin-2- yl)amino)benzo[d]thiazolo-6- carbonitrile
351.1

37

embedded image

137
N-(4-(pyrrolidin-1- ylmethyl)pyridin-2-yl)-6-(4H- 1,2,4-triazol-4- yl)benzo[d]thiazol-2-amine
378.1

38

embedded image

143
2-((4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
394.95

39

embedded image

144
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-((tetrahydro-2H-pyran-4- yl)oxy)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
409.1

40

embedded image

146
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridazin-4- yl)thiazolo[5,4-b]pyridin-2- amine
449.1

41

embedded image

147
1-(4-(2-((5-ethylthiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)-2- methoxyethanone
413.1

42

embedded image

148
1-((2-((5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4- yl)methyl)pyrrolidin-2-one
403.1

43

embedded image

149
1-((2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4- yl)methyl)pyrrolidin-2-one
392.1

44

embedded image

150
2-methoxy-1-(4-(2-((5-(pyridin- 4-yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperidin- 1-yl)ethanone
461.1

45

embedded image

151
N²-(benzo[d]thiazol-2-yl)-N⁴- (bicyclo[2.2.1]heptan-2-yl)-N⁶- ((R)-pyrrolidin-3-yl)-1,3,5- triazine-2,4,6-triamine

46

embedded image

152
N²-(bicyclo[2.2.1]heptan-2-yl)- N⁴-(6-methoxybenzo[d]thiazol- 2-yl)-N⁶-(pyrrolidin-3-yl)-1,3,5- triazine-2,4,6-triamine

47

embedded image

153
N²-(bicyclo[2.2.1]heptan-2-yl)- N⁴-(6-chlorobenzo[d]thiazol-2- yl)-N⁶-(pyrrolidin-3-yl)-1,3,5- triazine-2,4,6-triamine

48

embedded image

154
2-((4-(bicyclo[2.2.1]heptan-2- ylamino)-6-(pyrrolidin-3- ylamino)-1,3,5-triazin-2- yl)amino)benzo[d]thiazole-6- carboxylic acid

49

embedded image

155
N²-(benzo[d]thiazol-2-yl)-N⁴- ((1R,4S)-bicyclo[2.2.1]heptan- 2-yl)-N⁶-((R)-pyrrolidin-3- yl)pyrimidine-2,4,6-triamine

50

embedded image

156
2-((6-methoxybenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
370.1

51

embedded image

157
2-((6-cyanobenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
365.0

52

embedded image

158
2-((6-chlorobenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
374.0

53

embedded image

159
(R)-2-((2-((4-(methylamino)-6- (pyrrolidin-3-ylamino)-1,3,5- triazin-2- yl)amino)benzo[d]thiazol-6- yl)oxy)ethanol

54

embedded image

160
(S)-2-((6- methoxybenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
370.0

55

embedded image

161
(S)-2-((6-cyanobenzo[d]thiazol- 2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
365.0

56

embedded image

162
(R)-2-((6-cyanobenzo[d]thiazol- 2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
365.0

57

embedded image

163
(S)-2-((6-chlorobenzo[d]thiazol- 2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
373.9

58

embedded image

164
(R)-2-((6-chlorobenzo[d]thiazol- 2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
374.0

59

embedded image

165
N-(2-aminoethyl)-2-((6- cyanobenzo[d]thiazol-2- yl)amino)isonicotinamide
339.0

60

embedded image

166
N-(4-aminobutyl)-2-((6- cyanobenzo[d]thiazol-2- yl)amino)isonicotinamide
367.1

61

embedded image

167
2-((6-cyanobenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- ylmethyl)isonicotinamide
379.1

62

embedded image

168
2-((6-cyanobenzo[d]thiazol-2- yl)amino)-N-(piperidin-3- yl)isonicotinamide
379.1

63

embedded image

169
2-((6-cyanobenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-2- ylmethyl)isonicotinamide
379.0

64

embedded image

170
2-((4-(3-aminopiperidine-1- carbonyl)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
379.0

65

embedded image

171
N²-(6-methoxybenzo[d]thiazol- 2-yl)-N⁴-(pyrrolidin-3- yl)pyridine-2,4-diamine
342.0

66

embedded image

172
N²-(6-chlorobenzo[d]thiazol-2- yl)-N⁴-(pyrrolidin-3-yl)pyridine- 2,4-diamine
346.0

67

embedded image

173
(S)-2-((6-bromobenzo[d]thiazol- 2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
418.0

68

embedded image

174
(S)-2-((6-cyanobenzo[d]thiazol- 2-yl)amino)-N-methyl-N- (pyrrolidin-3-yl)isonicotinamide
379.0

69

embedded image

175
2-((4-(pyrrolidin-3- ylamino)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
337.1

70

embedded image

176
(S)-2-((6-(pyridin-4- yl)benzo[d]thiazol-2-yl)amino)- N-(pyrrolidin-3- yl)isonicotinamide
417.1

71

embedded image

177
(S)-2-((6-(pyridin-3- yl)benzo[d]thiazol-2-yl)amino)- N-(pyrrolidin-3- yl)isonicotinamide
417.1

72

embedded image

178
(S)-2-((6-(1-methyl-1H-pyrazol- 4-yl)benzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
420.1

73

embedded image

179
(S)-2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-yl)amino)- N-(pyrrolidin-3- yl)isonicotinamide
406.2

74

embedded image

180
2-((7-methoxybenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
370.0

75

embedded image

181
6-bromo-N-(4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
391.0

76

embedded image

182
(S)-2-((6-cyanobenzo[d]thiazol- 2-yl)amino)-6-methyl-N- (pyrrolidin-3-yl)isonicotinamide
379.1

77

embedded image

183
(S)-2-((7-cyanobenzo[d]thiazol- 2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
365.0

78

embedded image

184
2-((4-(cyclopentylamino)pyridin- 2-yl)amino)benzo[d]thiazole-6- carbonitrile
336.0

79

embedded image

185
1-(4-((2-((6- bromobenzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)piperazin-1- yl)ethanone
445.9

80

embedded image

186
1-(4-((2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)piperazin-1- yl)ethanone

81

embedded image

187
N-(4-(piperidin-1- ylmethyl)pyridin-2-yl)-6-(1H- pyrazol-4-yl)benzo[d]thiazol-2- amine

82

embedded image

188
2-((5-methyl-4-(pyrrolidin-3- ylamino)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
351.1

83

embedded image

189
6-(pyridin-3-yl)-N-(4-(pyrrolidin- 1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine

84

embedded image

190
1-((2-((6-bromobenzo[d]thiazol- 2-yl)amino)pyridin-4- yl)methyl)piperidin-4-ol

85

embedded image

191
2-(((2-((6- bromobenzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)(methyl)amino)ethanol

86

embedded image

192
6-bromo-N-(4- ((dimethylamino)methyl)pyridin- 2-yl)benzo[d]thiazol-2-amine

87

embedded image

193
6-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-yl)amino)- N-(pyrrolidin-3-yl)picolinamide
406.1

88

embedded image

194
6-(1H-pyrazol-5-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine

89

embedded image

195
2-((4-((2- aminopropyl)amino)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
325.1

90

embedded image

196
2-((4-((1-aminopropan-2- yl)amino)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
325.1

91

embedded image

197
N-((2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)methanesulfonamide
412.1

92

embedded image

198
N-(4-(piperidin-1- ylmethyl)pyridin-2-yl)-6-(pyridin- 4-yl)benzo[d]thiazol-2-amine
402.1

93

embedded image

199
N-(4- ((dimethylamino)methyl)pyridin- 2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
362.1

94

embedded image

200
4-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-yl)amino)- N-(pyrrolidin-3-yl)picolinamide
406.1

95

embedded image

201
6-(6-methoxypyridin-3-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
418.2

96

embedded image

202
N-(4-(4-methylpiperazin-1- yl)pyridin-2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
403.1

97

embedded image

203
6-(pyrimidin-5-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
389.1

98

embedded image

204
N-(4-((4-methylpiperazin-1- yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
417.1

99

embedded image

205
6-(2-methylpyridin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
402.1

100

embedded image

206
2-(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)acetic acid
363.0

101

embedded image

207
1,1-dimethyl-3-((2-((6-(pyridin- 4-yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)urea
405.1

102

embedded image

208
6-(3-methoxypyridin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
418.1

103

embedded image

209
6-(2-methoxypyridin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
418.1

104

embedded image

210
6-(2-chloropyridin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
422.0

105

embedded image

211
6-(3-methylpyridin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
402.1

106

embedded image

212
2-(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)-N-(2- (pyrrolidin-1-yl)ethyl)acetamide
459.1

107

embedded image

213
N-(4- ((methylamino)methyl)pyridin-2- yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
348.1

108

embedded image

214
3-(2-((4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)amino)benzo[d]thiazol-6- yl)benzonitrile
412.1

109

embedded image

215
N-(4-morpholinopyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
390.1

110

embedded image

216
N-(4-((3-methoxypyrrolidin-1- yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
418.1

111

embedded image

217
N-(4-((4- (methylsulfonyl)piperazin-1- yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
481.0

112

embedded image

218
6-(2-methoxypyrimidin-5-yl)-N- (4-(pyrrolidin-1-ylmethyl)pyridin- 2-yl)benzo[d]thiazol-2-amine
419.1

113

embedded image

219
3-(piperidin-1-yl)-N-((2-((6- (pyridin-4-yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)propanamide
473.2

114

embedded image

220
6-(benzo[d][1,2,5]oxadiazol-5- yl)-N-(4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
429.1

115

embedded image

221
1-methyl-4-(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)piperazin- 2-one
417.1

116

embedded image

222
2-(4-(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanol
433.1

117

embedded image

223
N-methyl-4-((2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)piperazine-1- carboxamide
460.2

118

embedded image

224
Methyl 2-(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)acetate
377.1

119

embedded image

225
2-(methyl(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)amino)ethanol
378.1

120

embedded image

226
1-((2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)pyrrolidin-3-ol
404.1

121

embedded image

227
N-(4-((4-methylpiperazin-1- yl)methyl)pyridin-2-yl)-6- (pyrimidin-5-yl)benzo[d]thiazol- 2-amine
418.2

123

embedded image

228
2-((2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)amino)ethanol
364.1

124

embedded image

229
7-methyl-6-(pyridin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
402.1

125

embedded image

230
5-methyl-6-(pyridin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
402.1

126

embedded image

231
N-(pyridin-2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
305.0

127

embedded image

232
6-(2-aminopyrimidin-5-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
404.1

128

embedded image

233
2-(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)-1- (pyrrolidin-1-yl)ethanone
416.1

129

embedded image

234
N-(4-(pyrrolidin-1- ylmethyl)pyridin-2-yl)-6-(2- (trifluoromethyl)pyridin-4- yl)benzo[d]thiazol-2-amine
456.1

130

embedded image

235
1-methyl-N-((2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)pyrrolidine-2- carboxamide
445.1

131

embedded image

236
5-(pyridin-4-yl)-N-(4-(pyrrolidin- 1-ylmethyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
389.1

132

embedded image

237
5-(pyrimidin-5-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
390.1

133

embedded image

238
N-(4-(aminomethyl)pyridin-2-yl)- 6-(pyrimidin-5- yl)benzo[d]thiazol-2-amine
335.1

134

embedded image

239
N-methyl-2-(2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)acetamide
376.1

135

embedded image

240
N-(2-hydroxyethyl)-2-(2-((6- (pyridin-4-yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)acetamide
406.0

136

embedded image

242
N-(4-(pyrrolidin-1- ylmethyl)pyridin-2-yl)-6-(1H- 1,2,4-triazol-1- yl)benzo[d]thiazol-2-amine
378.1

137

embedded image

243
1-(3-hydroxypyrrolidin-1-yl)-2- (2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)ethanone
432.0

138

embedded image

244
N-((2-((6-(pyrimidin-5- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)methanesulfonamide
413.0

139

embedded image

245
N-(4-morpholinopyridin-2-yl)-6- (4H-1,2,4-triazol-4- yl)benzo[d]thiazol-2-amine
380.1

140

embedded image

246
N-(4-(4-methylpiperazin-1- yl)pyridin-2-yl)-6-(4H-1,2,4- triazol-4-yl)benzo[d]thiazol-2- amine
393.2

141

embedded image

247
N-(4-(piperazin-1-yl)pyridin-2- yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
389.1

142

embedded image

248
N-(4-(4-methylpiperazin-1- yl)pyridin-2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
393.0

143

embedded image

249
N-(4-(piperazin-1-yl)pyridin-2- yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
379.1

144

embedded image

250
6-(1H-imidazol-1-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
377.2

145

embedded image

251
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-morpholinopyridin-2- yl)benzo[d]thiazol-2-amine
393.1

146

embedded image

252
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-(4-methylpiperazin-1- yl)pyridin-2-yl)benzo[d]thiazol- 2-amine
406.1

147

embedded image

253
N-(4-(piperazin-1-yl)pyridin-2- yl)-5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
390.1

148

embedded image

254
N-(4-(pyrrolidin-3- ylamino)pyridin-2-yl)-6- cyanobenzo[d]thiazol-2-amine

149

embedded image

255
N-(4-(4-methylpiperazin-1- yl)pyridin-2-yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
392.1

150

embedded image

256
N-(4-morpholinopyridin-2-yl)-5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
391.0

151

embedded image

257
N-(4-(4-methylpiperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
404.0

152

embedded image

258
N-(4-(piperazin-1-yl)pyridin-2- yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
378.0

153

embedded image

259
6-(pyridazin-4-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
389.0

154

embedded image

260
N-(4- ((methylamino)methyl)pyridin-2- yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
337.0

155

embedded image

261
N-(4- ((dimethylamino)methyl)pyridin- 2-yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
351.1

156

embedded image

262
N-(pyrazin-2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
306.0

157

embedded image

263
N-(4-(azetidin-1- ylmethyl)pyridin-2-yl)-6-(1H- pyrazol-4-yl)benzo[d]thiazol-2- amine
363.0

158

embedded image

264
N-(4-(4-methyl-1,4-diazepan-1- yl)pyridin-2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
407.1

159

embedded image

265
N-(4-(4-benzylpiperazin-1- yl)pyridin-2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
469.1

160

embedded image

266
5-(2-((4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)amino)thiazolo[5,4-b]pyridin- 5-yl)pyrimidine-2-carbonitrile
415.0

161

embedded image

267
1-(4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)-2-(dimethylamino)ethanone
464.0

162

embedded image

268
2-hydroxy-N-((2-((6-(pyridin-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)acetamide
392.0

163

embedded image

269
2-(4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanol
423.1

164

embedded image

270
1-(4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)-2-methoxyethanone
451.1

165

embedded image

271
5-(2-((4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)amino)benzo[d]thiazol-6- yl)pyrimidine-2-carbonitrile
414.0

166

embedded image

272
(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)methanol
325.0

167

embedded image

273
N²-(6-(pyridin-4- yl)benzo[d]thiazol-2-yl)pyridine- 2,6-diamine
320.0

168

embedded image

274
6-(1H-pyrrol-3-yl)-N-(4- (pyrrolidin-1-ylmethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
376.1

169

embedded image

275
1-(4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)-2-hydroxyethanone
437.1

170

embedded image

276
N-(4- ((methylamino)methyl)pyridin-2- yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
338.0

171

embedded image

277
N-(4-(aminomethyl)pyridin-2-yl)- 5-(1H-pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
324.0

172

embedded image

278
1-(2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)ethanol
338.0

173

embedded image

279
N-(4-(4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
457.1

174

embedded image

280
2-(2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)propan-2- ol
352.0

175

embedded image

281
N-(4-(methoxymethyl)pyridin-2- yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
338.0

176

embedded image

282
1-(4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)-3-(dimethylamino)propan- 1-one
478.2

177

embedded image

283
(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)-3-fluoropyridin-4- yl)methanol
343.0

178

embedded image

284
1-(4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)-3-(pyrrolidin-1-yl)propan-1- one
504.2

179

embedded image

285
N-(4- ((dimethylamino)methyl)pyridin- 2-yl)-6-(5-methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
365.1

180

embedded image

286
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-((methylamino)methyl)pyridin- 2-yl)benzo[d]thiazol-2-amine
351.1

181

embedded image

287
N-(4-(aminomethyl)pyridin-2-yl)- 6-(5-methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
337.0

182

embedded image

288
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-(piperidin-1-ylmethyl)pyridin- 2-yl)benzo[d]thiazol-2-amine
405.1

183

embedded image

289
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-(morpholinomethyl)pyridin-2- yl)benzo[d]thiazol-2-amine
407.2

184

embedded image

290
N-(4- ((dimethylamino)methyl)pyridin- 2-yl)-5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
366.1

185

embedded image

291
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-(piperidin-1-ylmethyl)pyridin- 2-yl)thiazolo[5,4-b]pyridin-2- amine
406.1

186

embedded image

292
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
406.1

187

embedded image

293
N-(4-(isoindolin-2- ylmethyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
440.1

188

embedded image

294
N-(4-((3-methoxypyrrolidin-1- yl)methyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
422.2

189

embedded image

295
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-(morpholinomethyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
408.1

190

embedded image

296
N-(4-(aminomethyl)pyridin-2-yl)- 6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
323.1

191

embedded image

297
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-((methylamino)methyl)pyridin- 2-yl)thiazolo[5,4-b]pyridin-2- amine
352.1

192

embedded image

298
N-(4-(azepan-1- ylmethyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
420.1

193

embedded image

299
N-(4-(((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)methyl)pyridin-2-yl)- 5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
432.2

194

embedded image

300
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-((3-phenylpyrrolidin-1- yl)methyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
468.1

195

embedded image

301
N-(4-(azepan-1- ylmethyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
419.2

196

embedded image

302
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2- yl)benzo[d]thiazol-2-amine
405.2

197

embedded image

303
N-(4-(isoindolin-2- ylmethyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
439.1

198

embedded image

304
N-(4-((3-methoxypyrrolidin-1- yl)-methyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
421.2

199

embedded image

305
1-((2-((6-(5-methyl-1H-pyrazol- 4-yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)pyrrolidin-3-ol
407.1

200

embedded image

306
N-(4-(azetidin-1- ylmethyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
378.1

201

embedded image

307
1-((2-((5-(5-methyl-1H-pyrazol- 4-yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4- yl)methyl)pyrrolidin-3-ol
408.1

202

embedded image

308
N-(4-(azetidin-1- ylmethyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
377.1

203

embedded image

309
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-((3-phenylpyrrolidin-1- yl)methyl)pyridin-2- yl)benzo[d]thiazol-2-amine
467.1

204

embedded image

310
N-(4-((4-(2- methoxyethyl)piperazin-1- yl)methyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
464.1

205

embedded image

311
N-(4-((4-(2- methoxyethyl)piperazin-1- yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
461.2

206

embedded image

312
N-(4-((4-(2- methoxyethyl)piperazin-1- yl)methyl)pyridin-2-yl)-6-(1H- pyrazol-4-yl)benzo[d]thiazol-2- amine
450.2

207

embedded image

313
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-((4-(methylsulfonyl)piperazin- 1-yl)methyl)pyridin-2- yl)benzo[d]thiazol-2-amine
484.0

208

embedded image

314
N-(4-(aminomethyl)pyridin-2-yl)- 5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
338.1

209

embedded image

315
N-(4-((1S,4R)-2- azabicyclo[2.2.1]heptan-2- ylmethyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-d]pyridin-2- amine
418.1

210

embedded image

316
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-6-(5-methyl-1H- pyrazol-4-yl)benzo[d]thiazol-2- amine
450.1

211

embedded image

317
2-methoxy-1-(4-(2-((6-(5- methyl-1H-pyrazol-4-yl) thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
465.0

212

embedded image

318
N-(4-((1S,4R)-2- azabicyclo[2.2.1]heptan-2- ylmethyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine

213

embedded image

319
N-(4-(((1S,4R)- bicyclo[2.2.1]heptan-2- ylamino)methyl)pyridin-2-yl)-6- (5-methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine

214

embedded image

320
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
436.1

215

embedded image

321
N-(4-((3,3-dimethylpyrrolidin-1- yl)methyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
420.2

216

embedded image

322
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
447.1

217

embedded image

323
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-(4-(methylsulfonyl)piperazin- 1-yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
471.1

218

embedded image

324
N-(4-((3,3-dimethylpyrrolidin-1- yl)methyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
419.2

219

embedded image

325
2-methoxy-1-(4-((2-((6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)piperazin-1- yl)ethanone
478.2

220

embedded image

326
6-(1H-pyrazol-4-yl)-N-(4- ((pyridin-3-yloxy)methyl)pyridin- 2-yl)benzo[d]thiazol-2-amine
401.0

221

embedded image

327
N-(4-(4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
467.1

222

embedded image

328
N-(4-(4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
456.1

223

embedded image

329
N-(4-((4- (methylsulfonyl)piperazin-1- yl)methyl)pyridin-2-yl)-6-(1H- pyrazol-4-yl)benzo[d]thiazol-2- amine
470.1

224

embedded image

330
N-(4-((4- (methylsulfonyl)piperazin-1- yl)methyl)pyridin-2-yl)-5-(1H- pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
471.1

225

embedded image

331
2-methoxy-1-(4-(2-((6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
464.2

226

embedded image

332
2-methoxy-1-(4-((2-((6-(pyridin- 4-yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)piperazin-1- yl)ethanone
475.2

227

embedded image

334
1-(4-((2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)piperazin-1-yl)-2- methoxyethanone
464.2

228

embedded image

335
2-methoxy-1-(4-((2-((5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4- yl)methyl)piperazin-1- yl)ethanone
479.2

229

embedded image

336
1-(4-((2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4- yl)methyl)piperazin-1-yl)-2- methoxyethanone
465.2

230

embedded image

337
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-(4-(methylsulfonyl)piperazin- 1-yl)pyridin-2- yl)benzo[d]thiazol-2-amine
470.1

231

embedded image

338
1-(4-(2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)-2-methoxyethanone
450.1

232

embedded image

339
4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)-1- methylpiperazin-2-one
407.1

233

embedded image

340
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-((4-(methylsulfonyl)piperazin- 1-yl)methyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
485.1

234

embedded image

341
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-(piperazin-1-yl)pyridin-2- yl)benzo[d]thiazol-2-amine

235

embedded image

342
1-((2-((6-(1H-pyrazol-4- yl)benzo[d]thiazol-2- yl)amino)pyridin-4- yl)methyl)pyrrolidin-3-ol
393.1

236

embedded image

343
(R)-6-(5-methyl-1H-pyrazol-4- yl)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2- yl)benzo[d]thiazol-2-amine
405.1

237

embedded image

344
(R)-5-(5-methyl-1H-pyrazol-4- yl)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
406.1

238

embedded image

345
(S)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
421.1

239

embedded image

346
(R)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-6-(5- methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
421.1

240

embedded image

347
(S)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
422.1

241

embedded image

348
(R)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2-yl)-5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
403.2

242

embedded image

349
N-(4-(isopropoxymethyl)pyridin- 2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
367.0

243

embedded image

350
(S)-6-(5-methyl-1H-pyrazol-4- yl)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2- yl)benzo[d]thiazol-2-amine
405.1

244

embedded image

351
(R)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
422.1

245

embedded image

352
(R)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
402.1

246

embedded image

353
(S)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2-yl)-5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
403.1

247

embedded image

354
(S)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
418.1

248

embedded image

355
(R)-N-(4-((3-methoxypyrrolidin- 1-yl)methyl)pyridin-2-yl)-6- (pyridin-4-yl)benzo[d]thiazol-2- amine
418.1

249

embedded image

356
N-(4- ((cyclopentyloxy)methyl)pyridin- 2-yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
392.1

250

embedded image

357
6-(1H-pyrazol-4-yl)-N-(4- (((tetrahydro-2H-pyran-4- yl)oxy)methyl)pyridin-2- yl)benzo[d]thiazol-2-amine
408.1

251

embedded image

358
(S)-5-(5-methyl-1H-pyrazol-4- yl)-N-(4-((2-methylpyrrolidin-1- yl)methyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
406.1

252

embedded image

359
N-(4-(isopropoxymethyl)pyridin- 2-yl)-6-(5-methyl-1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
380.1

253

embedded image

360
N-(4-(4-(2- isopropoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
465.2

254

embedded image

361
5-(pyridin-4-yl)-N-(4-(4-(3,3,3- trifluoropropyl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
486.2

255

embedded image

362
N-(4-(4-(2- isopropoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(5-methyl-1H- pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
479.2

256

embedded image

363
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-(4-(3,3,3- trifluoropropyl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
489.0

257

embedded image

364
N-(4-(4-(2- isopropoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
476.2

258

embedded image

365
N-(4-(4-(1-methoxypropan-2- yl)piperazin-1-yl)pyridin-2-yl)-5- (5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
465.1

259

embedded image

366
6-(5-methyl-1H-pyrazol-4-yl)-N- (4-(4-(3,3,3- trifluoropropyl)piperazin-1- yl)pyridin-2-yl)benzo[d]thiazol- 2-amine
488.1

260

embedded image

367
(S)-N-(4-(3-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
482.1

261

embedded image

368
N-(4-(4-(2- isopropoxyethyl)piperazin-1- yl)pyridin-2-yl)-6-(1H-pyrazol-4- yl)benzo[d]thiazol-2-amine
464.1

262

embedded image

369
N-(4-(4- (isopropylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(5-methyl-1H- pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
499.2

263

embedded image

370
2,2-dimethyl-1-(4-(2-((5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)propan-1-one
477.1

264

embedded image

371
N-(4-(4-(2- isopropoxyethyl)piperazin-1- yl)pyridin-2-yl)-6-(pyridin-4- yl)benzo[d]thiazol-2-amine
475.2

265

embedded image

372
6-(pyridin-4-yl)-N-(4-(4-(3,3,3- trifluoropropyl)piperazin-1- yl)pyridin-2-yl)benzo[d]thiazol- 2-amine
485.1

266

embedded image

373
(S)-2-methoxy-1-(2-methyl-4-(2- ((5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
479.2

267

embedded image

374
(S)-2-methoxy-1-(2-methyl-4-(2- ((5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)ethanone
476.1

268

embedded image

375
(S)-5-(5-methyl-1H-pyrazol-4- yl)-N-(4-(3-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
485

269

embedded image

376
(R)-N-(4-(4-(2-methoxyethyl)-3- methylpiperazin-1-yl)pyridin-2- yl)-5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
465.1

270

embedded image

377
6-(1H-pyrazol-4-yl)-N-(4-(4- (3,3,3-trifluoropropyl)piperazin- 1-yl)pyridin-2- yl)benzo[d]thiazol-2-amine
474.1

271

embedded image

378
N-(4-(4-(2- isopropoxyethyl)piperazin-1- yl)pyridin-2-yl)-6-(5-methyl-1H- pyrazol-4-yl)benzo[d]thiazol-2- amine
478.2

272

embedded image

379
(R)-2-methoxy-1-(3-methyl-4-(2- ((5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
479.2

273

embedded image

380
(R)-N-(4-(2-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
482.1

274

embedded image

381
(S)-N-(4-(4-(2-methoxyethyl)-3- methylpiperazin-1-yl)pyridin-2- yl)-5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
465.2

275

embedded image

382
(S)-N-(4-(4-(2-methoxyethyl)-3- methylpiperazin-1-yl)pyridin-2- yl)-5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
462.1

276

embedded image

383
(R)-N-(4-(4-(2-methoxyethyl)-3- methylpiperazin-1-yl)pyridin-2- yl)-5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
462.1

277

embedded image

384
1-(4-(2-((5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)-2-isopropoxyethanone
479.1

278

embedded image

385
2-isopropoxy-1-(4-(2-((5-(5- methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
493.1

279

embedded image

386
2-isopropoxy-1-(4-(2-((5- (pyridin-4-yl)thiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)ethanone
490.1

280

embedded image

387
(R)-2-methoxy-1-(3-methyl-4-(2- ((5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)ethanone
476.1

281

embedded image

388
(R)-5-(5-methyl-1H-pyrazol-4- yl)-N-(4-(2-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
485.1

282

embedded image

389
(R)-2-methoxy-1-(2-methyl-4-(2- ((5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)piperazin- 1-yl)ethanone
479.2

283

embedded image

390
(R)-2-methoxy-1-(2-methyl-4-(2- ((5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)ethanone
476.1

284

embedded image

391
2-methyl-1-(4-(2-((5-(2- methylpyridin-4-yl)thiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)ethanone
476.1

285

embedded image

392
(R)-N-(4-(3-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
482.0

286

embedded image

393
(S)-5-(5-methyl-1H-pyrazol-4- yl)-N-(4-(3-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
485.1

287

embedded image

394
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(2- methylpyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
462.1

288

embedded image

395
5-(2-methylpyridin-4-yl)-N-(4-(4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
482.0

289

embedded image

396
2-methoxy-1-(4-(2-((5- (pyridazin-4-yl)thiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)ethanone
463.0

290

embedded image

397
N-(4-(4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridazin-4- yl)thiazolo[5,4-b]pyridin-2- amine
469.1

291

embedded image

398
(S)-N-(4-(4-(2-methoxyethyl)-2- methylpiperazin-1-yl)pyridin-2- yl)-5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
462.1

292

embedded image

399
(S)-N-(4-(4-(2-methoxyethyl)-2- methylpiperazin-1-yl)pyridin-2- yl)-5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
465.1

293

embedded image

400
(R)-N-(4-(4-(2-methoxyethyl)-2- methylpiperazin-1-yl)pyridin-2- yl)-5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
462.1

294

embedded image

401
N-(4-(4-(2- methoxyethyl)piperidin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
447.1

295

embedded image

402
N-(4-(4-(2- methoxyethyl)piperidin-1- yl)pyridin-2-yl)-5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
436.1

296

embedded image

403
N⁴-(2-methoxyethyl)-N⁴-methyl- N²-(5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-yl)pyridine-2,4- diamine
393.1

297

embedded image

404
N-(4-((1S,4S)-5-(2- methoxyethyl)-2,5- diazabicyclo[2.2.1]heptan-2- yl)pyridin-2-yl)-5-(5-methyl- 1H-pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
463.1

298

embedded image

405
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-(4-(pyridin-2-yl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
470.2

299

embedded image

406
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-5-(pyrimidin-5- yl)thiazolo[5,4-b]pyridin-2- amine
449.1

300

embedded image

407
N-(4-(4-(2- methoxyethyl)piperidin-1- yl)pyridin-2-yl)-5-(5-methyl- 1H-pyrazol-4-yl)thiazolo[5,4- b]pyridin-2-amine
450.1

301

embedded image

408
N⁴-(2-methoxyethyl)-N⁴-methyl- N²-(5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- yl)pyridine-2,4-diamine
396.1

302

embedded image

409
N²-(5-(1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2-yl)- N⁴-(2-methoxyethyl)-N⁴- methylpyridine-2,4-diamine
382.0

303

embedded image

410
(R)-N-(4-(4-(2-methoxyethyl)-2- methylpiperazin-1-yl)pyridin-2- yl)-5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
465.2

304

embedded image

411
(S)-N-(4-(2-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- amine
482.0

305

embedded image

412
(S)-5-(5-methyl-1H-pyrazol-4- yl)-N-(4-(2-methyl-4- (methylsulfonyl)piperazin-1- yl)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
485.1

306

embedded image

413
2-((4-morpholinopyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
337.9

307

embedded image

414
2-((4-(pyrrolidine-1- carbonyl)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
349.9

308

embedded image

415
(2-((5-bromothiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)(pyrrolidin-1-yl)methanone
403.78

309

embedded image

416
N-(4-(cyclopentyloxy)pyridin-2- yl)-5-(pyridin-4-yl)thiazolo[5,4- b]pyridin-2-amine
390.0

310

embedded image

417
N-(4-(cyclopentyloxy)pyridin-2- yl)-5-(5-methyl-1H-pyrazol-4- yl)thiazolo[5,4-b]pyridin-2- amine
393.1

311

embedded image

418
5-ethynyl-N-(4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
336.0

312

embedded image

419
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)-6- methylbenzo[d]thiazol-2-amine
384.02

313

embedded image

420
2-((4,6-dimethylpyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
281.02

314

embedded image

421
2-((4-(1,4-dioxa-8- azaspiro[4.5]decan-8-yl)pyridin- 2-yl)amino)benzo[d]thiazole-6- carbonitrile
394.0

315

embedded image

422
2-((4-(4-oxopiperidin-1- yl)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
349.97

316

embedded image

423
N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)- [1,3]dioxolo[4′,5′:4,5]benzo[1,2- d]thiazol-6-amine
415.92

317

embedded image

424
6-isopropyl-N-(4-(4-(2- methoxyethyl)piperazin-1- yl)pyridin-2-yl)benzo[d]thiazol- 2-amine
412.01

318

embedded image

425
2-((4-(4-hydroxypiperidin-1- yl)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
351.92

319

embedded image

426
2-((4-(2-methoxyethoxy)pyridin- 2-yl)amino)benzo[d]thiazole-6- carbonitrile
326.91

320

embedded image

427
2-((4-isobutoxypyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
324.96

321

embedded image

428
N-(4-(pyrrolidin-1- ylmethyl)pyridin-2-yl)-5- vinylthiazolo[5,4-b]pyridin-2- amine

322

embedded image

429
5-ethyl-N-(4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine

323

embedded image

430
5-(pyridin-4-yl)-N-(4- ((tetrahydro-2H-pyran-4- yl)oxy)pyridin-2-yl)thiazolo[5,4- b]pyridin-2-amine
406.1

324

embedded image

431
N-(4-ethylpyridin-2-yl)-6-(1H- imidazol-4-yl)benzo[d]thiazol-2- amine
321.92

325

embedded image

432
1-(4-(2-((5-ethynylthiazolo[5,4- b]pyridin-2-yl)amino)pyridin-4- yl)piperazin-1-yl)-2- methoxyethanone
409.0

326

embedded image

433
4-(2-((5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)morpholin- 3-one
405.1

327

embedded image

434
2-((4-ethylpyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
280.95

328

embedded image

435
1,1-dimethyl-3-(2-((5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)urea
392.1

329

embedded image

436
5-(5-methyl-1H-pyrazol-4-yl)-N- (4-(4-(tetrahydro-2H-pyran-4- yl)piperazin-1-yl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2-amine
477.1

330

embedded image

437
Methyl (2-((5-(pyridin-4- yl)thiazolo[5,4-b]pyridin-2- yl)amino)pyridin-4-yl)carbamate
379.1

331

embedded image

438
2-((4-(hydroxymethyl)pyridin-2- yl)amino)benzo[d]thiazole-6- carbonitrile
283.0

332

embedded image

439
5-cyclopropyl-N-(4-(pyrrolidin-1- ylmethyl)pyridin-2- yl)thiazolo[5,4-b]pyridin-2- amine
352.1

Example 333
Synthesis of N-(4-ethylpyridin-2-yl)-6-(oxazol-5-yl)benzo[d]thiazol-2-amine (Compound 501, Structure 4 in Scheme II, R¹=ethyl, R⁴=5-oxazolyl)

embedded image

A mixture of 4-ethylpyridin-2-amine (100 mg, 0.821 mmol) and bis(1-benzotriazolyl)methanethione (250 mg, 0.891 mmol) were dissolved in 5 mL of anhydrous N,N-dimethylacetamide. The solution was stirred at room temperature for 1 hour. 4-(Oxazol-5-yl)aniline (130 mg, 0.821 mmol) was the added and the solution stirred at 50° C. for an additional hour. Water (15 mL) was then added and the resulting precipitate collected by vacuum filtration and dried under vacuum. The resulting tan powder was used without further purification. MS calculated for C₁₇H₁₆N₄OS: 325.1045; [M+H]⁺. found: 324.89.

embedded image

1-(4-Ethylpyridin-2-yl)-3-(4-(oxazol-5-yl)phenyl)thiourea (0.27 g, 0.8 mmol) was dissolved in 5 mL of acetic acid. Benzyltrimethylammonium tribromide (320 mg, 0.821 mmol) was then added directly. The mixture was stirred at 50° C. for 1 hour. The mixture was cooled to 0° C. and diluted with 15 mL of water. The resulting solution was then made basic through addition of solid KOH pellets. The resulting precipitate was collected by vacuum filtration, washed with water and dried under vacuum to afford the crude product as a tan solid. A portion of the solid was purified by rp-HPLC affording 0.6 mg of N-(4-ethylpyridin-2-yl)-6-(oxazol-5-yl)benzo[d]thiazol-2-amine 501 as a yellow solid. MS calculated for C₁₇H₁₄N₄OS: 323.0888; [M+H]+. found: 322.93. ¹H-NMR (400 MHz, MeOD) 8.25-8.23 (m, 2H), 8.17 (s, 1H), 7.75 (d, J=8.4, 1H), 7.66 (d, J=8.4, 1H) 7.50 (s, 1H), 6.97 (s, 1H), 6.88 (d, J=8.4, 1H), 2.68 (q, J=7.7, 2H), 1.28 (t, J=7.7, 3H).

Example 334
Synthesis of 6-(1H-pyrazol-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)imidazo[1,2-a]pyridin-2-amine (Compound 493, structure 10 in Scheme III, R¹═CH₂—N-pyrrolidinyl, R⁴=4-pyrazolyl)

embedded image

To a solution of 6-bromoimidazo[1,2-a]pyridin-2-amine (200 mg; 0.94 mmol) in dry THF (4 mL) was added NaH (90 mg; 3.76 mmol) in portions at 0° C. The reaction mixture was stirred at r.t. for half an hour. Then 2-chloro-4-(pyrrolidin-1-ylmethyl)pyridine (222 mg, 1.1 mmol) was added. The mixture was heated to 120° C. for 24 hrs. The mixture was quenched by addition of H₂O (20 mL) slowly at 0° C., extracted with DCM (30 mL×3). The combined organic phases were concentrated under reduced pressure and purified by column chromatography on silica (DCM:MeOH=15:1) to obtain 6-bromo-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)imidazo[1,2-a]pyridin-2-amine (110 mg, yield 80%) as a brown solid.

embedded image

To a solution of 6-bromo-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)imidazo[1,2-a]pyridin-2-amine (50 mg, 0.13 mmol) in mixed dioxane/H₂O (2 mL/0.5 mL) was added the pinacol boronate ester (59.2 mg, 0.2 mmol), K₂CO₃(55.6 mg, 0.4 mmol) and Pd(dppf)Cl₂(10.8 mg, 0.013 mmol) under nitrogen atmosphere. The mixture reacted under microwave condition at 140° C. for 2 hrs. After cooling, the solvent was removed under reduced pressure, and the residue was purified by prep-TLC to afford 6-(1H-pyrazol-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)imidazo[1,2-a]pyridin-2-amine 493 (8.5 mg, yield 17.7%). ¹H NMR (400 MHz MeOD) δ 8.93 (s, 1H), 8.47-8.45 (d, J=5.2, 1H), 8.12 (s, 2H), 8.06-8.03 (dd, J=9.2, 1H), 7.85-7.82 (dd, J=9.6, 1H), 7.14-7.11 (m, 2H), 4.43 (s, 2H), 3.55-3.30 (m, 4H), 2.14 (s, 4H).

Examples 335-352

Compounds 484-502 were prepared in a similar fashion as described in Examples 333-334 and their structures, names, and found molecular mass ion numbers are summarized in Table 2 (Example: E.g.; Compound: Cmpd).

TABLE 2

E.g.
Structure
Cmpd
Name
[M + H]⁺

335

embedded image

484
2-((4-(hydoxymethyl)pyridin-2- yl)amino)imidazo[1,2-a]pyridine-6- carbonitrile

336

embedded image

485
(S)-tert-butyl 3-(2-((6- cyanoimidazo[1,2-a]pyridin-2- yl)amino)isonicotinamido)pyrrolidine- 1-carboxylate
448.2

337

embedded image

486
(S)-2-((6-cyanoimidazo[1,2-a]pyridin- 2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide
348.2

338

embedded image

487
2-((4-(pyrrolidin-1-ylmethyl)pyridin-2- yl)amino)imidazo[1,2-a]pyridine-6- carbonitrile
319.2

339

embedded image

488
6-(pyridin-3-yl)-N-(4-(pyrrolidin-1- ylmethyl)pyridin-2-yl)imidazo[1,2- a]pyridin-2-amine
371.1

340

embedded image

489
1-(4-((2-((6-(pyridin-4-yl)imidazo[1,2- a]pyridin-2-yl)amino)pyridin-4- yl)methyl)piperazin-1-yl)ethanone
428.1

341

embedded image

490
1-(4-((2-((6-(pyridin-3-yl)imidazo[1,2- a]pyridin-2-yl)amino)pyridin-4- yl)methyl)piperazin-1-yl)ethanone
428.1

342

embedded image

491
(2-((6-(pyridin-4-yl)imidazo[1,2- a]pyridin-2-yl)amino)pyridin-4- yl)methanol
318.1

343

embedded image

492
N-(4-(piperazin-1-ylmethyl)pyridin-2- yl)-6-(pyridin-4-yl)imidazo[1,2- a]pyridin-2-amine
386.1

345

embedded image

494
1-(4-((2-((6-(1H-pyrazol-4- yl)imidazo[1,2-a]pyridin-2- yl)amino)pyridin-4-yl)methyl)piperazin- 1-yl)ethanone
417.7

346

embedded image

495
N-(4-(piperazin-1-ylmethyl)pyridin-2- yl)-6-(1H-pyrazol-4-yl)imidazo[1,2- a]pyridin-2-amine
375.1

347

embedded image

496
(2-((6-(1H-pyrazol-4-yl)imidazo[1,2- a]pyridin-2-yl)amino)pyridin-4- yl)methanol
307.1

348

embedded image

497
N-(4-(4-(methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-6-(pyridin-4- yl)imidazo[1,2-a]pyridin-2-amine
450.1

349

embedded image

498
2-methoxy-1-(4-(2-((6-(pyridin-4- yl)imidazo[1,2-a]pyridin-2- yl)amino)pyridin-4-yl)piperazin-1- yl)ethanone
444.2

350

embedded image

499
N-(4-(4-(methylsulfonyl)piperazin-1- yl)pyridin-2-yl)-6-(1H-pyrazol-4- yl)imidazo[1,2-a]pyridin-2-amine
439.1

351

embedded image

500
6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4- (methylsulfonyl)piperazin-1-yl)pyridin- 2-yl)imidazo[1,2-a]pyridin-2-amine
453.1

352

embedded image

502
(2-((6-(pyridin-3-yl)imidazo[1,2- a]pyridin-2-yl)amino)pyridin-4- yl)methanol
318.0

Examples 353-430

Compounds 503-580 were prepared in a similar fashion as described in Examples 1-2 and 333-334, and their structures and names are summarized in Table 3 (Example: E.g.; Compound: Cmpd).

TABLE 3

E.g.
Structure
Cmpd
Name

353

embedded image

503
3((5-trifluoromethylbenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)benzamide

354

embedded image

504
3((6-nitrobenzo[d]thiazol-2-yl)amino)-N- (pyrrolidin-3-yl)benzamide

355

embedded image

505
2-(3-(pyrrolidin-1-ylmethyl)phenylamino)-6- cyanobenzo[d]thiazole

356

embedded image

506
(R)-2-(benzo[d]thiazol-2-ylamino)-4-(3- hydroxypropylamino)-6-(pyrrolidin-3- ylamino)-1,3,5-triazine

357

embedded image

507
(R)-2-(benzo[d]thiazol-2-ylamino)-4-(2- hydroxyethylamino)-6-(pyrrolidin-3-ylamino)- 1,3,5-triazine

358

embedded image

508
(R)-2-(benzo[d]thiazol-2-ylamino)-4- methylamino-6-(pyrrolidin-3-ylamino)-1,3,5- triazine

359

embedded image

509
2-((6-fluorobenzo[d]thiazol-2-yl)amino)-N- (pyrrolidin-3-yl)isonicotinamide

360

embedded image

510
2-((6-hydroxybenzo[d]thiazol-2-yl)amino)-N- (pyrrolidin-3-yl)isonicotinamide

361

embedded image

511
2-((6-trifluoromethylbenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide

362

embedded image

512
2-((6-trifluoromethoxybenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide

363

embedded image

513
2-((6-methoxybenzo[d]thiazol-2-yl)amino)-6- methyl-N-(pyrrolidin-3-yl)isonicotinamide

364

embedded image

514
2-((6-hydroxymethylbenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide

365

embedded image

515
(R)-2-((6-methoxybenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide

366

embedded image

516
(S)-2-((6-phenylbenzo[d]thiazol-2-yl)amino)- N-(pyrrolidin-3-yl)isonicotinamide

367

embedded image

517
(S)-2-((6-methylsulfonylbenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide

368

embedded image

518
2-((quinolin-2-yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide

369

embedded image

519
(S)-2-((6-cyanoquinolin-2-yl)amino)-N- (pyrrolidin-3-yl)isonicotinamide

370

embedded image

520
(R)-2-((6-N-methyl-N-(2- methoxyethyl)benzo[d]thiazol-2- yl)amino)-N- (pyrrolidin-3-yl)isonicotinamide

371

embedded image

521
(R)-2-((6-morpholinobenzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3- yl)isonicotinamide

372

embedded image

522
2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)-4- pyrimidinecarboxamide

373

embedded image

523
5-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)nicotinamide

374

embedded image

524
2-((6-bromobenzo[d]thiazol-2-yl)amino)-4- (N-methyl-N-(2- methoxyethyl)aminomethyl)pyridine

375

embedded image

525
2-((6-bromobenzo[d]thiazol-2-yl)amino)-4- [morpholinomethyl)pyridine

376

embedded image

526
2-((6-bromobenzo[d]thiazol-2-yl)amino)-4- (4-methylpiperazinomethyl)pyridine

377

embedded image

527
2-((6-(3,5-dimethylisoxazol-4- yl)benzo[d]thiazol-2-yl)amino)-4- (pyrrolidin-1-ylmethyl)pyridine

378

embedded image

528
2-((6-(3-chloropyridin-4-yl)benzo[d]thiazol-2- yl)amino)-4-(pyrrolidin-ylmethyl)pyridine

379

embedded image

529
2-((6-(3-methoxyphenyl)benzo[d]thiazol-2- yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine

380

embedded image

530
2-((6-(3,5-dimethylpyrazol-4- yl)benzo[d]thiazol-2-yl)amino)- 4-(pyrrolidin-1-ylmethyl)pyridine

381

embedded image

531
2-((6-(2,2,2-trifluoroethyl)benzo[d]thiazol-2- yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine

382

embedded image

532
2-((6-(2,2,2-trifluoroethyl)benzo[d]thiazol-2- yl)amino)-4-(4-methoxyacetylpiperazin-1- yl)pyridine

383

embedded image

533
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- cyanoacetylpiperidin-4-yl)pyridine

384

embedded image

534
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- cyanoacetylpiperidin-4-yl)pyridine

385

embedded image

535
2-((6-(imidazol-1-yl)benzo[d]thiazol-2- yl)amino)-4-hydroxymethylpyridine

386

embedded image

536
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- (4-methoxyphenyl(acetylpiperidin-4- yl)pyridine

387

embedded image

537
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- (3-cyclopentyl-1-oxopropyl)piperdin-4- yl)pyridine

388

embedded image

538
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- (1-oxopropyl)piperidin-4-yl)pyridine

389

embedded image

539
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- cyclopropylcarbonylpiperidin-4-yl)pyridine

390

embedded image

540
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- trifluoroacetylpiperidin-4-yl)pyridine

391

embedded image

541
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- ethylsulfonylpiperidin-4-yl)pyridine

392

embedded image

542
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- methoxyacetylpiperidin-4-yl)pyridine

393

embedded image

543
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4- (piperidin-4-yl)pyridine

394

embedded image

544
2-((6-(pyrazol-1-yl)benzo[d]thiazol-2- yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine

395

embedded image

545
2-((6-(3-fluoropyridin-4-yl)benzo[d]thiazol-2- yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine

396

embedded image

546
2-((6-(pyrazol-4-yl)benzo[d]thiazol-2- yl)amino)-4-hydroxymethyl-3-fluoropyridine

397

embedded image

547
2-((6-bromobenzo[d]thiazol-2-yl)amino)-4- hydroxymethylpyridine

398

embedded image

548
2-((6-bromobenzo[d]thiazol-2-yl)amino)-4- ethylpyridine

399

embedded image

549
5-((6-cyanobenzo[d]thiazol-2-yl)amino)-3- methylisoxazole

400

embedded image

550
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-5- methyl-4-phenylthiazole

401

embedded image

551
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-5-(4- methoxyphenyl)-1,3,4-thiadiazol

402

embedded image

552
2-((6-(oxazol-5-yl)benzo[d]thiazol-2- yl)amino)-4-(4-(2-methoxyethyl)piperazin-1- yl)pyridine

403

embedded image

553
2-((6-(2-methyl-1,3,4-oxadiazol-5- yl)benzo[d]thiazol-2-yl)amino)- 4-ethylpyridine

404

embedded image

554
2-(3-hydroxymethylphenyl)amino-6- cyanobenzo[d]thiazole

405

embedded image

555
2-((6-(1,3,4-oxadiazol-2-yl)benzo[d]thiazol- 2-yl)amino)-4-ethylpyridine

406

embedded image

556
2-((6-(1,3,4-thiadiazol-2-yl)benzo[d]thiazol- 2-yl)amino)-4-ethylpyridine

407

embedded image

557
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4- (pyrrolidin-1-ylmethyl)pyridine

408

embedded image

558
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4- (pyrrolidin-1-ylthiocarbonyl)pyridine

409

embedded image

559
2-(3,5-dimethoxymethylphenyl)amino-6- cyanobenzo[d]thiazole

410

embedded image

560
4-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2- yl)amino)-N-(pyrrolidin-3-yl)-6- pyrimidinecarboxamide

411

embedded image

561
5-(5-methyl-1H-pyrazol-4-yl)-2-(4- hydroxymethylpyridin-2- ylamino)thiazolo[5,4-b]pyridine

412

embedded image

562
5-(pyridin-4-yl)-2-(5- isopropyloxymethylisoxazol-3- ylamino)thiazolo[5,4-b]pyridine

413

embedded image

563
5-(1H-pyrazol-4-yl)-2-(3-(4- methoxyacetylpiperazin-1- ylphenyl)amino)thiazolo[5,4-b]pyridine

414

embedded image

564
5-ethyl-2-(3-(4-methoxyacetylpiperazin-1- ylphenyl)amino)thiazolo[5,4-b]pyridine

415

embedded image

565
5-ethyl-2-(4-(1-methoxyacetylpiperidin-4- ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine

416

embedded image

566
5-ethyl-2-(4-(pyrrolidin-1-ylpyridin-2- yl)amino)thiazolo[5,4-b]pyridine

417

embedded image

567
5-(pyridine-4-yl)-2-(4-(3-dimethylamino-3- oxopropyl)pyridin-2-yl)amino)thiazolo[5,4- b]pyridine

418

embedded image

568
5-(1-methylimidazol-5-yl)-2-(4-4- methoxyacetylpiperazin-1-ylpyridin-2- yl)amino)thiazolo(5,4-b)pyridine

419

embedded image

569
5-(pyrimidin-4-yl)-2-(4-4- methoxyacetylpiperazin- 1-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine

420

embedded image

570
5-(thiazol-5-yl)-2-(4-(4- methoxyacetylpiperazin-1-ylpyridin-2- yl)amino)thiazolo[5,4-b]pyridine

421

embedded image

571
5-propyl-2-(4-(4-methoxyacetylpiperazin-1- ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine

422

embedded image

572
5-(1H-pyrazol-4-yl)-2-(2-pyrrolidon-1- ylmethylpyridin-4-yl)amino)thiazolo[5,4- b]pyridine

423

embedded image

573
5-(pyridin-4-yl)-2-(4-(1-methyl-2- oxopiperidin-4-ylpyridin- 2-yl)amino)thiazolo[5,4-b]pyridine

424

embedded image

574
5-(1-methylimidazol-5-yl)-2-(4-(4-(2- dimethylaminocarbonylethyl)pyridin-2- yl)amino)thiazolo[5,4-b]pyridine

425

embedded image

575
5-(pyridine-4-yl)-2-(4-(4- methoxyacetylpiperazin-1-ylpyridin-2- yl)amino)oxazolo[5,4-b]pyridine

426

embedded image

576
2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1- phenylcarbonylpiperidin-4-yl)pyridine

427

embedded image

577
6-cyano-2-(4-(4-methoxyacetyl-piperazin-1- yl)pyridin-2-ylamino)imidazo[1,2-a]pyridine

428

embedded image

578
6-cyano-2-(4-(4-methoxyethyl)piperazin-1- yl)pyridin-2-ylamino)imidazo[1,2-a]pyridine

429

embedded image

579
6-(1H-pyrazol-4-yl)-2-(4-morpholinopyridin- 2-ylamino)imidazo[1,2-a]pyridine

430

embedded image

580
5-(pyridin-3-yl)-2-(4-piperazin-1- ylmethylpyridin-2- yl)amino)thiazolo[5,4-b]pyridine

Example 431
Inhibition Assay

The following assay is useful for evaluating test compounds for inhibition of IRAK-1 or IRAK-4 kinase activity. A 96-well polystyrene microtiter plates are coated with neutravidin for IRAK-1 or streptavidin for IRAK-4 (10 mg/mL in PBS, overnight at 4° C.). The coating solution is removed and in 80 μL/well, a kinase reaction mixture is added (for IRAK-1: 20 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 2 mM EGTA, 1 mM NaF, 0.5 mM benzamidine, 1 mM DTT, 3 μM ATP, 1 mM of biotinylated substrate peptide bio-ARFSRFAGSSPSQSSMVAR, sequence derived from IRAK-1; for IRAK-4: 20 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 2 mM EGTA, 1 mM NaF, 0.5 mM benzamidine, 1 mM DTT, 10% glycerol, 10 μM ATP, 1 mM of biotinylated substrate peptide bio-RRRVTSPARRS, sequence derived from GFAP).

At 10 μL/well in DMSO test compounds are added covering a final concentration range from 1 nM to 30 mM. Recombinant, full-length IRAK-1 or IRAK-4 enzyme (baculovirus expression system) is added in 10 μL buffer containing 20 mM Tris-HCl, pH 7.5, 2 mM EGTA, 0.5 mM benzamidine, 1 mM DTT, 10 mM MgCl₂, and glycerol 10% (IRAK-4 only) to initiate the kinase reaction. The reaction mixture is incubated at room temperature for 60 min on a shaker. During this incubation the substrate peptide is being phosphorylated by the kinase and gets captured onto the surface of the wells by neutravidin or streptavidin, respectively. The plate is washed 3× with 150 μL distilled water to terminate the reaction and remove components of the reaction mixture. A conventional chemiluminescent ELISA detection technique is initiated by adding 100 μL/well primary antibody (monoclonal antibody YC10, generated to recognize the phosphorylated epitope in the substrate peptide; use at 1:20,000 dilution for IRAK-1 and 1:10,000 dilution for IRAK-4) premixed with horseradish peroxidase (HRP) conjugated anti-mouse secondary antibody (commercially available from several sources; use at 1:10,000 dilution) in PBS containing 2% BSA. The solution is incubated at room temperature for 40 min on a shaker, then washed 3× with 150 μL of water. 100 μL 10× diluted SuperSignal HRP substrate (from Pierce) is added and after 5 min incubation the chemiluminescent signal is captured by a Labsystems LuminoSkan luminometer. The point of 50% inhibition of IRAK-1 or IRAK-4 enzyme activity (IC₅₀) is determined. Table 4 summarizes data obtained using an assay substantially similar to the foregoing method (Compound: Cmpd).

TABLE 4

Cmpd
EC₅₀
Cmpd
EC₅₀
Cmpd
EC₅₀
Cmpd
EC₅₀

101
A
110
A
120
A
130
A

137
A
150
A
160
A
170
A

180
A
190
A
200
A
210
A

220
A
230
A
240
A
250
A

260
A
270
A
280
A
290
A

300
A
310
A
320
A
330
A

340
A
350
A
360
A
370
A

380
A
390
A
401
A
410
A

420
A
430
A
439
A
484
B

490
A
500
A
510
B
521
B

530
B
540
A
553
B
560
B

570
A
580
B

It is to be understood that both the foregoing general description and detailed description are exemplary and explanatory only and are not restrictive of the embodiments claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “includes,” and “included,” is not limiting. The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.

All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.

All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention.

Claims

1. A compound of Formula (I):
2. The compound of claim 1, wherein R4 is selected from hydrogen, halogen, OR6, CN, NR7R8, CH2OR6, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted C1-C6 alkyl, an optionally substituted C1-C6 haloalkyl, an optionally substituted C1-C6 heteroalkyl, an optionally substituted C1-C6 alkenyl, an optionally substituted C1-C6 alkynyl, CO2R6, SO3R6, SO2R6 and SO2NR7R8
3. The compound of claim 1, wherein if R4 is pyrazolyl, the pyrazolyl is not substituted with aryl or heteroaryl groups.
4. The compound of claim 1, wherein if R4 is oxazolyl, isoxazolyl, or imidazoyl, the oxazolyl, isoxazolyl, or imidazoyl radical is not substituted with aryl or heteroaryl groups.
5. The compound of claim 1, represented by Formula (I-A):
6. The compound of claim 1, represented by Formula (II):
7. The compound of claim 1, represented by Formula (III):
8. The compound of claim 1, wherein W is S.
9. The compound of claim 7, wherein X is N.
10. The compound of claim 1, wherein Y is CR9.
11. The compound of claim 1, wherein R4 is selected from the group consisting of pyridyl, pyrazolyl, cyano, triazolyl, and oxazolyl.
12. The compound of claim 1, wherein Y is N.
13. The compound of claim 1, wherein R4 is selected from the group consisting of pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, and C1-C6 alkyl.
14. The compound of claim 1, wherein the compound is selected from the group consisting of: N-(4-(hydroxymethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,6-(pyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,6-(1H-pyrazol-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(piperazin-1-ylmethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,1-(4-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,1-(4-methylpiperazin-1-yl)-2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)ethanone,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,5-(1H-pyrazol-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-morpholinopyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-morpholinopyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,(2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methanol,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-((dimethylamino)methyl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(isopropoxymethyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,2-methoxy-1-(4-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,2-methoxy-1-(4-((2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,2-methoxy-1-(4-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(R)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(isopropoxymethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-(isopropoxymethyl)-pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-(isopropoxymethyl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(1H-pyrazol-4-yl)-N-(4-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(isopropylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(isopropylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,2-methoxy-1-(4-(2-((5-(pyrimidin-5-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyrimidin-5-yl)thiazolo[5,4-b]pyridin-2-amine,2-((6-methyl-4-(pyrrolidin-3-ylamino)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-6-(4H-1,2,4-triazol-4-yl)benzo[d]thiazol-2-amine,2-((4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridazin-4-yl)thiazolo[5,4-b]pyridin-2-amine,1-(4-(2-((5-ethylthiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-2-methoxyethanone,1-((2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)methyl)pyrrolidin-2-one,1-((2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)methyl)pyrrolidin-2-one,2-methoxy-1-(4-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperidin-1-yl)ethanone,N2-(benzo[d]thiazol-2-yl)-N4-(bicyclo[2.2.1]heptan-2-yl)-N6—((R)-pyrrolidin-3-yl)-1,3,5-triazine-2,4,6-triamine,N2-(bicyclo[2.2.1]heptan-2-yl)-N4-(6-methoxybenzo[d]thiazol-2-yl)-N6-(pyrrolidin-3-yl)-1,3,5-triazine-2,4,6-triamine,N2-(bicyclo[2.2.1]heptan-2-yl)-N4-(6-chloro benzo[d]thiazol-2-yl)-N6-(pyrrolidin-3-yl)-1,3,5-triazine-2,4,6-triamine,2-((4-(bicyclo[2.2.1]heptan-2-ylamino)-6-(pyrrolidin-3-ylamino)-1,3,5-triazin-2-yl)amino)benzo[d]thiazole-6-carboxylic acid,N2-(benzo[d]thiazol-2-yl)-N4-(1R,4S)-bicyclo[2.2.1]heptan-2-yl)-N6—((R)-pyrrolidin-3-yl)pyrimidine-2,4,6-triamine,2-((6-methoxybenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-chlorobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(R)-2-((2-((4-(methylamino)-6-(pyrrolidin-3-ylamino)-1,3,5-triazin-2-yl)amino)benzo[d]thiazol-6-yl)oxy)ethanol,(S)-2-((6-methoxybenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-cyanobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(R)-2-((6-cyanobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-chlorobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(R)-2-((6-chlorobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,N-(2-aminoethyl)-2-((6-cyanobenzo[d]thiazol-2-yl)amino)isonicotinamide,N-(4-aminobutyl)-2-((6-cyanobenzo[d]thiazol-2-yl)amino)isonicotinamide,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-ylmethyl)isonicotinamide,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-N-(piperidin-3-yl)isonicotinamide,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-2-ylmethyl)isonicotinamide,2-((4-(3-aminopiperidine-1-carbonyl)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,N2-(6-methoxybenzo[d]thiazol-2-yl)-N4-(pyrrolidin-3-yl)pyridine-2,4-diamine,N2-(6-chlorobenzo[d]thiazol-2-yl)-N4-(pyrrolidin-3-yl)pyridine-2,4-diamine,(S)-2-((6-bromobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-cyanobenzo[d]thiazol-2-yl)amino)-N-methyl-N-(pyrrolidin-3-yl)isonicotinamide,2-((4-(pyrrolidin-3-ylamino)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,(S)-2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-(pyridin-3-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-(1-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((7-methoxybenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,6-bromo-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,(S)-2-((6-cyanobenzo[d]thiazol-2-yl)amino)-6-methyl-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((7-cyanobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((4-(cyclo pentylamino)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,1-(4-((2-((6-bromobenzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,1-(4-((2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,N-(4-(piperidin-1-ylmethyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,2-((5-methyl-4-(pyrrolidin-3-ylamino)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,6-(pyridin-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,1-((2-((6-bromobenzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperidin-4-ol,2-(((2-((6-bromobenzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)(methyl)amino)ethanol,6-bromo-N-(4-((dimethylamino)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,6-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)picolinamide,6-(1H-pyrazol-5-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,2-((4-((2-aminopropyl)amino)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,2-((4-((1-aminopropan-2-yl)amino)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,N-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)methanesulfonamide,N-(4-(piperidin-1-ylmethyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-((dimethylamino)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,4-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)picolinamide,6-(6-methoxypyridin-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(4-methylpiperazin-1-yl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,6-(pyrimidin-5-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-((4-methylpiperazin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,6-(2-methylpyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)acetic acid,1, 1-dimethyl-3-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)urea,6-(3-methoxypyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,6-(2-methoxypyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,6-(2-chloropyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,6-(3-methylpyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)-N-(2-(pyrrolidin-1-yl)ethyl)acetamide,N-(4-((methylamino)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,3-(2-((4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)amino)benzo[d]thiazol-6-yl)benzonitrile,N-(4-morpholinopyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,6-(2-methoxypyrimidin-5-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,3-(piperidin-1-yl)-N-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)propanamide,6-(benzo[c][1,2,5]oxadiazol-5-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,1-methyl-4-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)piperazin-2-one,2-(4-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanol,N-methyl-4-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperazine-1-carboxamide,methyl 2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)acetate,2-(methyl(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)amino)ethanol,1-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)pyrrolidin-3-ol,N-(4-((4-methylpiperazin-1-yl)methyl)pyridin-2-yl)-6-(pyrimidin-5-yl)benzo[d]thiazol-2-amine,2-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)amino)ethanol,7-methyl-6-(pyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,5-methyl-6-(pyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,6-(2-aminopyrimidin-5-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)-1-(pyrrolidin-1-yl)ethanone,N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-yl)benzo[d]thiazol-2-amine,1-methyl-N-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)pyrrolidine-2-carboxamide,5-(pyridin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,5-(pyrimidin-5-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(aminomethyl)pyridin-2-yl)-6-(pyrimidin-5-yl)benzo[d]thiazol-2-amine,N-methyl-2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)acetamide,N-(2-hydroxyethyl)-2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)acetamide,N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-6-(1H-1,2,4-triazol-1-yl)benzo[d]thiazol-2-amine,1-(3-hydroxypyrrolidin-1-yl)-2-(2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)ethanone,N-((2-((6-(pyrimidin-5-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)methanesulfonamide,N-(4-morpholinopyridin-2-yl)-6-(4H-1,2,4-triazol-4-yl)benzo[d]thiazol-2-amine,N-(4-(4-methylpiperazin-1-yl)pyridin-2-yl)-6-(4H-1,2,4-triazol-4-yl)benzo[d]thiazol-2-amine,N-(4-(piperazin-1-yl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-(4-methylpiperazin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(piperazin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,6-(1H-imidazol-1-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-morpholinopyridin-2-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-methylpiperazin-1-yl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5, 4-b]pyridin-2-amine,N-(4-(pyrrolidin-3-ylamino)pyridin-2-yl)-6-cyanobenzo[d]thiazol-2-amine,N-(4-(4-methylpiperazin-1-yl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-morpholinopyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-methylpiperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(piperazin-1-yl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,6-(pyridazin-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-((methylamino)methyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-((dimethylamino)methyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(pyrazin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-(azetidin-1-ylmethyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-(4-methyl-1,4-diazepan-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(2-((4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)amino)thiazolo[5,4-b]pyridin-5-yl)pyrimidine-2-carbonitrile,1-(4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-2-(dimethylamino)ethanone,2-hydroxy-N-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)acetamide,2-(4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanol,1-(4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-2-methoxyethanone,5-(2-((4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)amino)benzo[d]thiazol-6-yl)pyrimidine-2-carbonitrile,(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)methanol,N2-(6-(pyridin-4-yl)benzo[d]thiazol-2-yl)pyridine-2,6-diamine,6-(1H-pyrrol-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,1-(4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-2-hydroxyethanone,N-(4-((methylamino)methyl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(aminomethyl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,1-(2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)ethanol,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,2-(2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)propan-2-ol,N-(4-(methoxymethyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,1-(4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-3-(dimethylamino)propan-1-one,(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)-3-fluoropyridin-4-yl)methanol,1-(4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one,N-(4-((dimethylamino)methyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-((methylamino)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(aminomethyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(piperidin-1-ylmethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(morpholinomethyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-((dimethylamino)methyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(piperidin-1-ylmethyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(isoindolin-2-ylmethyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(morpholino methyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(aminomethyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-((methylamino)methyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(azepan-1-ylmethyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(((1S,4R)-bicyclo[2.2.1]heptan-2-ylamino)methyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-((3-phenylpyrrolidin-1-yl)methyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(azepan-1-ylmethyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(isoindolin-2-ylmethyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,1-((2-((6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)pyrrolidin-3-ol,N-(4-(azetidin-1-ylmethyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,1-((2-((5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)methyl)pyrrolidin-3-ol,N-(4-(azetidin-1-ylmethyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-((3-phenylpyrrolidin-1-yl)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(aminomethyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-ylmethyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,2-methoxy-1-(4-(2-((6-(5-methyl-1H-pyrazol-4-yl) thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,N-(4-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-ylmethyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-(((1S,4R)-bicyclo[2.2.1]heptan-2-ylamino)methyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-((3,3-dimethylpyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-((3,3-dimethylpyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,2-methoxy-1-(4-((2-((6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,6-(1H-pyrazol-4-yl)-N-(4-((pyridin-3-yloxy)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,2-methoxy-1-(4-(2-((6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,2-methoxy-1-(4-((2-((6-(pyridin-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,1-(4-((2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)-2-methoxyethanone,2-methoxy-1-(4-((2-((5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5, 4-b]pyridin-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,1-(4-((2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)-2-methoxyethanone,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)benzo[d]thiazol-2-amine,1-(4-(2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-2-methoxyethanone,4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)-1-methylpiperazin-2-one,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(piperazin-1-yl)pyridin-2-yl)benzo[d]thiazol-2-amine,1-((2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)pyridin-4-yl)methyl)pyrrolidin-3-ol,(R)-6-(5-methyl-1H-pyrazol-4-yl)-N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,(R)-5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,(R)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,(S)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5, 4-b]pyridin-2-amine,(R)—N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(isopropoxymethyl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5, 4-b]pyridin-2-amine,(S)-6-(5-methyl-1H-pyrazol-4-yl)-N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,(R)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5, 4-b]pyridin-2-amine,(R)—N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,(S)—N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,(R)—N-(4-((3-methoxypyrrolidin-1-yl)methyl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,N-(4-((cyclopentyloxy)methyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,6-(1H-pyrazol-4-yl)-N-(4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)pyridin-2-yl)benzo[d]thiazol-2-amine,(S)-5-(5-methyl-1H-pyrazol-4-yl)-N-(4-((2-methylpyrrolidin-1-yl)methyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(isopropoxymethyl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-(4-(2-isopropoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(pyridin-4-yl)-N-(4-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-isopropoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-isopropoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(1-methoxypropan-2-yl)piperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)pyridin-2-yl)benzo[d]thiazol-2-amine,(S)—N-(4-(3-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-isopropoxyethyl)piperazin-1-yl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,N-(4-(4-(isopropylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,2,2-dimethyl-1-(4-(2-((5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)propan-1-one,N-(4-(4-(2-isopropoxyethyl)piperazin-1-yl)pyridin-2-yl)-6-(pyridin-4-yl)benzo[d]thiazol-2-amine,6-(pyridin-4-yl)-N-(4-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)pyridin-2-yl)benzo[d]thiazol-2-amine,(S)-2-methoxy-1-(2-methyl-4-(2-((5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,(S)-2-methoxy-1-(2-methyl-4-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,(S)-5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(3-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,(R)—N-(4-(4-(2-methoxyethyl)-3-methylpiperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,6-(1H-pyrazol-4-yl)-N-(4-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)pyridin-2-yl)benzo[d]thiazol-2-amine,N-(4-(4-(2-isopropoxyethyl)piperazin-1-yl)pyridin-2-yl)-6-(5-methyl-1H-pyrazol-4-yl)benzo[d]thiazol-2-amine,(R)-2-methoxy-1-(3-methyl-4-(2-((5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,(R)—N-(4-(2-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-(4-(2-methoxyethyl)-3-methylpiperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-(4-(2-methoxyethyl)-3-methylpiperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(R)—N-(4-(4-(2-methoxyethyl)-3-methylpiperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,1-(4-(2-((5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-2-isopropoxyethanone,2-isopropoxy-1-(4-(2-((5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,2-isopropoxy-1-(4-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,(R)-2-methoxy-1-(3-methyl-4-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,(R)-5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(2-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,(R)-2-methoxy-1-(2-methyl-4-(2-((5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,(R)-2-methoxy-1-(2-methyl-4-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,2-methoxy-1-(4-(2-((5-(2-methylpyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,(R)—N-(4-(3-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)-5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(3-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(2-methylpyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(2-methylpyridin-4-yl)-N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,2-methoxy-1-(4-(2-((5-(pyridazin-4-yl)thiazolo[5, 4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridazin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-(4-(2-methoxyethyl)-2-methylpiperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-(4-(2-methoxyethyl)-2-methylpiperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,(R)—N-(4-(4-(2-methoxyethyl)-2-methylpiperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperidin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperidin-1-yl)pyridin-2-yl)-5-(1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N4-(2-methoxyethyl)-N4-methyl-N2-(5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)pyridine-2,4-diamine,N-(4-((1S,4S)-5-(2-methoxyethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-(pyridin-2-yl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-5-(pyrimidin-5-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperidin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,N4-(2-methoxyethyl)-N4-methyl-N2-(5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)pyridine-2,4-diamine,N2-(5-(1H-pyrazol-4-yl)thiazolo[5, 4-b]pyridin-2-yl)-N4-(2-methoxyethyl)-N4-methylpyridine-2,4-diamine,(R)—N-(4-(4-(2-methoxyethyl)-2-methylpiperazin-1-yl)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)—N-(4-(2-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,(S)-5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(2-methyl-4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,2-((4-morpholinopyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,2-((4-(pyrrolidine-1-carbonyl)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,(2-((5-bromothiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)(pyrrolidin-1-yl)methanone,N-(4-(cyclopentyloxy)pyridin-2-yl)-5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(cyclopentyloxy)pyridin-2-yl)-5-(5-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-amine,5-ethynyl-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-6-methylbenzo[d]thiazol-2-amine,2-((4,6-dimethylpyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,2-((4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,2-((4-(4-oxo piperidin-1-yl)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-[1,3]dioxolo[4′,5′;4,5]benzo[1,2-d]thiazol-6-amine,6-isopropyl-N-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)benzo[d]thiazol-2-amine,2-((4-(4-hydroxypiperidin-1-yl)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,2-((4-(2-methoxyethoxy)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,2-((4-isobutoxypyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)-5-vinylthiazolo[5,4-b]pyridin-2-amine,5-ethyl-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,5-(pyridin-4-yl)-N-(4-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-ethylpyridin-2-yl)-6-(1H-imidazol-4-yl)benzo[d]thiazol-2-amine,1-(4-(2-((5-ethynylthiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)-2-methoxyethanone,4-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)morpholin-3-one,2-((4-ethylpyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,1,1-dimethyl-3-(2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)urea,5-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,methyl (2-((5-(pyridin-4-yl)thiazolo[5,4-b]pyridin-2-yl)amino)pyridin-4-yl)carbamate,2-((4-(hydroxymethyl)pyridin-2-yl)amino)benzo[d]thiazole-6-carbonitrile,5-cyclopropyl-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)thiazolo[5,4-b]pyridin-2-amine,N-(4-ethylpyridin-2-yl)-6-(oxazol-5-yl)benzo[d]thiazol-2-amine,3-((5-trifluoromethylbenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)benzamide,3-((6-nitrobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)benzamide,2-(3-(pyrrolidin-1-ylmethyl)phenylamino)-6-cyanobenzo[d]thiazole,(R)-2-(benzo[d]thiazol-2-ylamino)-4-(3-hydroxypropylamino)-6-(pyrrolidin-3-ylamino)-1,3,5-triazine,(R)-2-(benzo[d]thiazol-2-ylamino)-4-(2-hydroxyethylamino)-6-(pyrrolidin-3-ylamino)-1,3,5-triazine,(R)-2-(benzo[d]thiazol-2-ylamino)-4-methylamino-6-(pyrrolidin-3-ylamino)-1,3,5-triazine,2-((6-fluorobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-hydroxybenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-trifluoromethylbenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-trifluoromethoxybenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-methoxybenzo[d]thiazol-2-yl)amino)-6-methyl-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-hydroxymethylbenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(R)-2-((6-methoxybenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-phenylbenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-methylsulfonylbenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((quinolin-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(S)-2-((6-cyanoquinolin-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(R)-2-((6-N-methyl-N-(2-methoxyethyl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,(R)-2-((6-morpholinobenzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)-4-pyrimidinecarboxamide,5-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)nicotinamide,2-((6-bromobenzo[d]thiazol-2-yl)amino)-4-(N-methyl-N-(2-methoxyethyl)aminomethyl)pyridine,2-((6-bromobenzo[d]thiazol-2-yl)amino)-4-(morpholinomethyl)pyridine,2-((6-bromobenzo[d]thiazol-2-yl)amino)-4-(4-methylpiperazinomethyl)pyridine,2-((6-(3,5-dimethylisoxazol-4-yl)benzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-(3-chloropyridin-4-yl)benzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-(3-methoxyphenyl)benzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-(3,5-dimethylpyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-(2,2,2-trifluoroethyl)benzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-(2,2,2-trifluoroethyl)benzo[d]thiazol-2-yl)amino)-4-(4-methoxyacetylpiperazin-1-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-cyanoacetylpiperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-cyanomethylpiperidin-4-yl)pyridine,2-((6-(imidazol-1-yl)benzo[d]thiazol-2-yl)amino)-4-hydroxymethylpyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-(4-methoxyphenyl)acetylpiperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-(3-cyclopentyl-1-oxopropyl)piperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-(1-oxopropyl)piperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-cyclopropylcarbonylpiperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-trifluoro acetylpiperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-ethylsulfonylpiperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-methoxyacetylpiperidin-4-yl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(piperidin-4-yl)pyridine,2-((6-(pyrazol-1-yl)benzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-(3-fluoropyridin-4-yl)benzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-(pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-4-hydroxymethyl-3-fluoropyridine,2-((6-bromobenzo[d]thiazol-2-yl)amino)-4-hydroxymethylpyridine,2-((6-bromobenzo[d]thiazol-2-yl)amino)-4-ethylpyridine,5-((6-cyanobenzo[d]thiazol-2-yl)amino)-3-methylisoxazole,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-5-methyl-4-phenylthiazole,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-5-(4-methoxyphenyl)-1,3,4-thiadiazol,2-((6-(oxazol-5-yl)benzo[d]thiazol-2-yl)amino)-4-(4-(2-methoxyethyl)piperazin-1-yl)pyridine,2-((6-(2-methyl-1,3,4-oxadiazol-5-yl)benzo[d]thiazol-2-yl)amino)-4-ethylpyridine,2-(3-hydroxymethylphenyl)amino-6-cyanobenzo[d]thiazole,2-((6-(1, 3,4-oxadiazol-2-yl)benzo[d]thiazol-2-yl)amino)-4-ethylpyridine,2-((6-(1, 3,4-thiadiazol-2-yl)benzo[d]thiazol-2-yl)amino)-4-ethylpyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylmethyl)pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(pyrrolidin-1-ylthiocarbonyl)pyridine,2-(3,5-dimethoxymethylphenyl)amino-6-cyanobenzo[d]thiazole,4-((6-(1H-pyrazol-4-yl)benzo[d]thiazol-2-yl)amino)-N-(pyrrolidin-3-yl)-6-pyrimidinecarboxamide,5-(5-methyl-1H-pyrazol-4-yl)-2-(4-hydroxymethylpyridin-2-ylamino)thiazolo[5,4-b]pyridine,5-(pyridin-4-yl)-2-(5-isopropyloxymethylisoxazol-3-ylamino)thiazolo[5,4-b]pyridine,5-(1H-pyrazol-4-yl)-2-(3-(4-methoxyacetylpiperazin-1-ylphenyl)amino)thiazolo[5,4-b]pyridine,5-ethyl-2-(3-(4-methoxyacetylpiperazin-1-ylphenyl)amino)thiazolo[5,4-b]pyridine,5-ethyl-2-(4-(1-methoxyacetylpiperidin-4-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-ethyl-2-(4-(pyrrolidon-1-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-(pyridine-4-yl)-2-(4-(3-dimethylamino-3-oxopropyl)pyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-(1-methylimidazol-5-yl)-2-(4-(4-methoxyacetylpiperazin-1-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-(pyrimidin-4-yl)-2-(4-(4-methoxyacetylpiperazin-1-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-(thiazol-5-yl)-2-(4-(4-methoxyacetylpiperazin-1-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-propyl-2-(4-(4-methoxyacetylpiperazin-1-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-(1H-pyrazol-4-yl)-2-(2-pyrrolidon-1-ylmethylpyridin-4-yl)amino)thiazolo[5,4-b]pyridine,5-(pyridin-4-yl)-2-(4-(1-methyl-2-oxopiperidin-4-ylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-(1-methylimidazol-5-yl)-2-(4-(2-dimethylaminocarbonylethyl)pyridin-2-yl)amino)thiazolo[5,4-b]pyridine,5-(pyridine-4-yl)-2-(4-(4-methoxyacetylpiperazin-1-ylpyridin-2-yl)amino)oxazolo[5,4-b]pyridine,2-((6-cyanobenzo[d]thiazol-2-yl)amino)-4-(1-phenylcarbonylpiperidin-4-yl)pyridine,6-cyano-2-(4-(4-methoxyacetyl-piperazin-1-yl)pyridin-2-ylamino)imidazo[1,2-a]pyridine,6-cyano-2-(4-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-ylamino)imidazo[1,2-a]pyridine,6-(1H-pyrazol-4-yl)-2-(4-morpholinopyridin-2-ylamino)imidazo[1,2-a]pyridine, and5-(pyridin-3-yl)-2-(4-(piperazin-1-ylmethylpyridin-2-yl)amino)thiazolo[5,4-b]pyridine.
15. The compound of claim 1, represented by Formula (IV):
16. The compound of claim 15, wherein X is N.
17. The compound of claim 15, wherein the compound is selected from the group consisting of: 6-(1H-pyrazol-4-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)imidazo[1,2-a]pyridin-2-amine,2-((4-(hydroxymethyl)pyridin-2-yl)amino)imidazo[1,2-a]pyridine-6-carbonitrile, (S)-tert-butyl 3-(2-((6-cyanoimidazo[1,2-a]pyridin-2-yl)amino)isonicotinamido)pyrrolidine-1-carboxylate,(S)-2-((6-cyanoimidazo[1,2-a]pyridin-2-yl)amino)-N-(pyrrolidin-3-yl)isonicotinamide,2-((4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)amino)imidazo[1,2-a]pyridine-6-carbonitrile,6-(pyridin-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)pyridin-2-yl)imidazo[1,2-a]pyridin-2-amine,1-(4-((2-((6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,1-(4-((2-((6-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,(2-((6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)amino)pyridin-4-yl)methanol,N-(4-(piperazin-1-ylmethyl)pyridin-2-yl)-6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-amine,1-(4-((2-((6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl)amino)pyridin-4-yl)methyl)piperazin-1-yl)ethanone,N-(4-(piperazin-1-ylmethyl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-amine,(2-((6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl)amino)pyridin-4-yl)methanol,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-amine,2-methoxy-1-(4-(2-((6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)amino)pyridin-4-yl)piperazin-1-yl)ethanone,N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-amine,6-(5-methyl-1H-pyrazol-4-yl)-N-(4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)imidazo[1,2-a]pyridin-2-amine, and(2-((6-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)amino)pyridin-4-yl)methanol.
18. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
19. A method of treating a disorder responsive to inhibition of Interleukin-1 Receptor-Associated Kinase-mediated signal transduction comprising administering to a subject in need thereof an effective amount of the compound of claim 1.
20. The method of claim 19, wherein the disorder is an inflammatory disorder.
21. The method of claim 20, wherein the inflammatory disorder is selected from the group consisting of osteoarthritis, rheumatoid arthritis, multiple sclerosis, corneal ulcers, uveitis, and inflammatory bowel disease.
22. The method of claim 19, wherein the disorder is a skin disorder.
23. The method of claim 22, wherein the skin disorder is selected from the group consisting of dermatitis, cutaneous eosinophilias, Lichen planus, urticaria, psoriasis, pruritus, angiodermas, chronic skin ulcers, conjunctivitis, vasculitides, and erythemas.
24. The method of claim 19, wherein the disorder is a respiratory disorder.
25. The method of claim 24, wherein the respiratory disorder is selected from the group consisting of asthma, rhinitis, chronic obstructive pulmonary disease, bronchitis, nasal polyposis, nasal congestion, farmer's lung, fibroid lung and cough.
26. The method of claim 19, wherein the disorder is selected from the group consisting of diabetes, obesity, allergic disease, cancer, and sepsis.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/137,318 filed Dec. 20, 2013 which is a continuation of U.S. application Ser. No. 13/885,138 filed May 13, 2013 which is the U.S. National Phase of Application No. PCT/US2011/061532 entitled “HETEROCYCLE AMINES AND USES THEREOF” filed Nov. 18, 2011 and published in English on May 24, 2012 as WO2012/068546 which claims the benefit of U.S. Provisional Application No. 61/415,685 filed Nov. 19, 2010 entitled “HETEROCYCLE AMINES AND USES THEREOF” which is incorporated herein by reference in its entirety.

Provisional Applications (1)

	Number	Date	Country
	61415685	Nov 2010	US

Continuations (2)

	Number	Date	Country
Parent	14137318	Dec 2013	US
Child	15006940		US
Parent	13885138		US
Child	14137318		US

HETEROCYCLE AMINES AND USES THEREOF

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Provisional Applications (1)

Continuations (2)